



HU000030905T2

(19) **HU****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**(11) Lajstromszám: **E 030 905**(13) **T2**

## EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 10 744865**(22) A bejelentés napja: **2010. 07. 01.**

(96) Az európai bejelentés bejelentési száma:

**EP 20100744865**

(97) Az európai bejelentés közzétételi adatai:

**EP 2449098 A1** **2011. 01. 06.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

**EP 2449098 B1** **2016. 12. 07.**(51) Int. Cl.: **C07K 1/14** (2006.01)**A61K 38/44** (2006.01)**A61K 38/45** (2006.01)**C12N 9/10** (2006.01)**C12P 21/02** (2006.01)**C12N 9/88** (2006.01)**C12N 9/02** (2006.01)**A61K 38/51** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

**PCT/EP 10/003864**

(87) A nemzetközi közzétételi szám:

**WO 11000523**

(30) Elsőbbségi adatok:

**09164430** **2009. 07. 02.****EP****497275** **2009. 07. 02.****US**

(73) Jogosult(ak):

**OxThera Intellectual Property AB, 114 36  
Stockholm (SE)**

(72) Feltaláló(k):

**SIDHU, Harmeet, Gainesville FL 32606 (US)****LI, Qingshan, Gainesville FL 32607 (US)****COWLEY, Aaron, Blake, Gainesville FL 32608 (US)****GÖLANDER, Carl-Gustaf, S-756 53 Uppsala (SE)**

(74) Képviselő:

**SBGK Szabadalmi Ügyvivői Iroda, Budapest**

(54) **Rekombináns oxalát-degradáló enzimek tisztítása és izolálása és porlasztva szárított oxalát-degradáló enzimeket tartalmazó részecskék**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 449 098 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:

**07.12.2016 Bulletin 2016/49**

(21) Application number: **10744865.6**

(22) Date of filing: **01.07.2010**

(51) Int Cl.:

**C07K 1/14** (2006.01) **C12N 9/02** (2006.01)  
**C12N 9/10** (2006.01) **C12N 9/88** (2006.01)  
**A61K 38/44** (2006.01) **A61K 38/45** (2006.01)  
**A61K 38/51** (2006.01) **C12P 21/02** (2006.01)

(86) International application number:

**PCT/EP2010/003864**

(87) International publication number:

**WO 2011/000523 (06.01.2011 Gazette 2011/01)**

(54) **PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES**

Reinigung und Isolierung von rekombinanten Oxalat abbauenden Enzymen und sprühgetrocknete Teilchen mit Oxalat abbauenden Enzymen

Purification et isolation d'enzymes à dégradation d'oxalate recombinante et particules à séchage par atomisation contenant des enzymes à dégradation d'oxalate

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO SE SI SK SM TR**

(30) Priority: **02.07.2009 EP 09164430**

**02.07.2009 US 497275**

(43) Date of publication of application:

**09.05.2012 Bulletin 2012/19**

(73) Proprietor: **OxThera Intellectual Property AB**

**114 36 Stockholm (SE)**

(72) Inventors:

- **SIDHU, Harmeet**  
**Gainesville**  
**FL 32606 (US)**
- **LI, Qingshan**  
**Gainesville**  
**FL 32607 (US)**
- **COWLEY, Aaron, Blake**  
**Gainesville**  
**FL 32608 (US)**

- **GÖLANDER, Carl-Gustaf**  
**S-756 53 Uppsala (SE)**

(74) Representative: **Brann AB**

**P.O. Box 3690**  
**Drottninggatan 27**  
**103 59 Stockholm (SE)**

(56) References cited:

**WO-A-2005/123116 WO-A-2007/070052**  
**WO-A-2007/075447 WO-A-2008/105911**  
**US-B1- 6 929 940**

- **AOKI T ET AL: "Purification of recombinant human pepsinogens and their application as immunoassay standards.", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL JUN 1998, vol. 45, no. 2, June 1998 (1998-06), pages 289-301, XP009122213, ISSN: 1039-9712**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description****Field of the invention**

**[0001]** The present invention relates to spray-dried particles comprising oxalate reducing enzymes for delivering the enzymes in an active form to the stomach, where the oxalate reducing enzymes exert their effect. Thus, the present invention provides means for reducing oxalate in the stomach. Moreover, the present invention relates to a method for isolating a recombinant protein that is insoluble in the cytoplasm of a host cell and is not found as an inclusion body, which is regarded as inactive, mis-folded protein precipitate, comprising,

- a) separating an insoluble recombinant protein not found as an inclusion body from soluble host cell proteins; and
- b) solubilising the separated recombinant protein.

**Background of the invention**

**[0002]** Kidney/urinary tract stone disease (urolithiasis) is a major health problem throughout the world. Most of the stones associated with urolithiasis are composed of calcium oxalate alone or calcium oxalate plus calcium phosphate. Other disease states have also been associated with excess oxalate. These include, vulvodynia, oxalosis associated with end-stage renal disease, cardiac conduction disorders, Crohn's disease, and other enteric disease states.

**[0003]** Oxalic acid, and/or its salts, oxalate, is found in a wide variety of foods, and is therefore, a component of many constituents in human and animal diets. Increased oxalate absorption may occur after foods containing elevated amounts of oxalic acid are eaten. Foods such as spinach and rhubarb are well known to contain high amounts of oxalate, but a multitude of other foods and beverages also contain oxalate. Because oxalate is found in such a wide variety of foods, diets that are low in oxalate and which are also palatable are hard to formulate. In addition, compliance with a low oxalate diet is often problematic.

**[0004]** The risk for formation of kidney stones revolves around a number of factors that are not yet completely understood. Kidney or urinary tract stone disease occurs in as many as 12 % of the population in Western countries and about 70% of these stones are composed of calcium oxalate or of calcium oxalate plus calcium phosphate. Some individuals (e.g. patients with intestinal disease such as Crohn's disease, inflammatory bowel disease, or steatorrhea and also patients that have undergone jejunioileal bypass surgery) absorb more of the oxalate in their diets than do others. For these individuals, the incidence of oxalate urolithiasis increases markedly. The increased disease incidence is due to increased levels of oxalate in kidneys and urine, and this, the most common hyperoxaluric syndrome in humans, is known as enteric hyperoxaluria. Oxalate is also a problem in patients with end-stage renal disease and there is recent evidence that elevated urinary oxalate is also involved in vulvar vestibulitis (vulvodynia).

**[0005]** Enteric coated or other compositions comprising oxalate reducing bacteria have been suggested for reducing oxalate concentrations during passage through the intestines before being absorbed systemically. Enteric coated compositions pass through the stomach in intact form, i.e. the coating is intact and accordingly, oxalate will not be degraded in the stomach. A better approach is to reduce oxalate in the stomach before it is absorbed in the intestines. Accordingly, there is a need for developing compositions that enable reduction of oxalate in the stomach in order to reduce, for example, dietary oxalate. Moreover, such compositions are suitable for use in the treatment of enteric and absorptive hyperoxalurias such as hyperoxalurias causing recurrent stone disease. An objective with such a treatment is for the patients to have normal or at least lowered urinary oxalate levels.

**Summary of the invention**

**[0006]** The present invention relates to spray-dried particles comprising one or more recombinant proteins selected from the group consisting of the C383S and the C383A mutant of the oxalate decarboxylase (OxDC) wild type recombinant protein according to SEQ. ID NO. 1 or SEQ. ID NO. 2, or a protein encoded by a sequence selected from SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18, or SEQ. ID NO. 19; and a polymeric material, wherein said proteins are prepared as nano- or micro-agglomerates.

**[0007]** The present invention also relates to compositions comprising spray-dried particles as defined above, and such compositions for use in a method for treatment of a human or animal subject by reducing oxalate present in the stomach thereby reducing the absorption of said oxalate, said method comprising orally administering the composition to the stomach of the human or animal subject.

**Description of the figures****[0008]**

Fig. 1 is a chromatogram of wild type OxDC eluted from Phenyl-sepharose column by segment gradient salt elution. Peaks 1 and 2 both contain OxDC, but peak 1 contains 80-90% of OxDC with higher specific activity (50-60 U/mg pure OxDC) and peak 2 contains 30-70% OxDC with lower specific activity (30-50 U/mg pure OxDC). OxDC in peak 2 is theorized to be damaged or folded incorrectly. Peak 3 is impurities (peaks 1-3 are indicated on the dotted curve). The different curves are indicated by dots, triangles, squares, diamonds and crosses.

Fig. 2 is a graph showing mean urinary excretion of oxalate of rats fed 0 mg oxalate (baseline, no ox), 2.3% potassium oxalate (HOD) and oxalate decarboxylase particles of the present Invention (Oxazyme) in conjunction with 2.3% potassium oxalate. Urinary oxalate is normalized against creatinine and is the accumulation of urine collected from days 4 and 9. Ox/Cr is Oxalate/creatinine.

**Detailed disclosure of the invention**

**[0009]** As appears from the above, the present invention provides spray-dried particles comprising one or more recombinant proteins selected from the group consisting of the C383S and the C383A mutant of the oxalate decarboxylase (OxDC) wild type recombinant protein according to SEQ. ID NO. 1 or SEQ. ID NO. 2, or a protein encoded by a sequence selected from SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18, or SEQ. ID NO. 19; and a polymeric material, wherein said proteins are prepared as nano- or micro-agglomerates;

iii) compositions comprising spray-dried particles as defined above, and such compositions for use in a method for treatment of a human or animal subject by reducing oxalate present in the stomach thereby reducing the absorption of said oxalate, said method comprising orally administering the composition to the stomach of the human or animal subject.

**[0010]** Thus, the present invention is further developments of previously described compositions for treating oxalate-related diseases see e.g. WO 2007/075447 (to the same Applicant). Moreover, the present Inventors have surprisingly found that specific mutations of the wild-type oxalate decarboxylase, notably by substituting a cysteine residue in position 383 with serine, alanine or arginine, confer physico-chemical properties to the enzyme that are particularly advantageous in the isolation and purification of the enzyme. Thus, the present isolation and purification method involves fewer steps than normally seen and makes use of variations in solubility of the enzymes in cytoplasm and in purification media.

**[0011]** Furthermore, the present inventors have found a more simple solution to deliver active oxalate degrading enzymes to the stomach. In WO 2007/075447 (to the same Applicant) compositions are described that contain particles having a content of an oxalate degrading enzymes. The particles contain a combination of various polymers and are protected by the harsh environment in the stomach by multiple layers of polymers and/or by cross-linking the polymers to strengthen the resistance towards pepsin and pH in the stomach. However, a more simple solution has been developed that makes use of a very specific group of polymers, notably poly(meth)acrylates, in combination with one or more oxalate degrading enzymes. The particles are prepared using a mild process, namely spray-drying. Even if the enzymes may not be completely protected from the environment in the stomach by incorporating them into spray-dried particles, the examples herein show a remarkable activity after the spray-drying method and after exposure to a simulated gastric environment.

**Definitions**

**[0012]** The term "oxalate reducing enzyme" as used herein is intended to denote any enzyme that is capable of reducing oxalate. It may reduce oxalate *per se* and/or it may function in an oxalate reduction pathway. In this context the term "oxalate" encompasses oxalic acid and/or any salts(s) thereof (oxalate).

**[0013]** Enzymes used in the particles, compositions and methods of the present invention include oxalate decarboxylase (abbreviated OxDC), mutated. Moreover, other enzymes, cofactors and co-enzymes that are substituents of oxalate degradation pathways or involved in oxalate metabolic pathways, particularly oxalate reduction, are also of relevance in combination with one or more of the above-mentioned enzymes. In the present context not only the enzymes are encompassed by this definition, but also polynucleotide sequences that encode oxalate-reducing genes and proteins.

**[0014]** The enzymes may be made by recombinant means. Normally, the enzymes will be employed as purified recombinant proteins. When used in a medical use (as a drug) or in food (as food supplement, functional food or as a

prophylactic measure), it is preferred that the one or more enzymes used are well-defined with respect to purity and activity.

**[0015]** Oxalate decarboxylase (EC 4.1.1.2) is mainly present in fungi. It has been reported and characterized in several fungi such as, *Myrothecium verrucaria*, certain strains of *Aspergillus niger*, white rot fungus, *Coriolus versicolor* and *Collybia velutipes*. This enzyme converts oxalate to formate and carbon dioxide in an oxygen dependent reaction. Oxalate decarboxylases also have been used in the clinical assay of oxalate in blood and urine and can be used to lower oxalate levels in foods and the environment. The YvrK protein (the *B. subtilis* oxalate decarboxylase) has been expressed as a functional recombinant protein in *E. coli*, purified to homogeneity and fully characterized.

**[0016]** These enzymes have been studied in the oxalate reducing bacteria, *Pseudomonas oxalaticus* commonly found in the soil and in *Oxalobacter formigenes*, residing in the GI tract of vertebrates and humans. The enzymes have been fully reviewed in, "The enzymes of oxalate metabolism: Unexpected structures and metabolism" Svedruzic D. et al. Arch Biochem Biophys. 2005 Jan 1;433(1):176-92, which is herein incorporated in its entirety. The enzymes, made by recombinant techniques, may be modified by recombinant or chemical means and may contain side groups or other appended molecules. For example, enzymes may be modified to have linker molecules for attachment to other molecules or chemical compounds.

**[0017]** As appears from the examples herein specific mutations of oxalate decarboxylase that lead to a replacement amino acid for cysteine 383 are advantageous C383S, C383A. Accordingly, such recombinant enzymes are specifically of interest in the various aspects of the present invention.

**[0018]** As used herein the singular of the term "an enzyme" refers to multiple copies of the enzyme molecule, as is commonly understood in reference to protein molecules.

**[0019]** As used herein, enzyme includes recombinant enzyme proteins.

**[0020]** As used herein, the term "one or more enzymes" means that one type of enzyme may be present, or more than one type of enzyme, such as a composition comprising oxalate decarboxylase, or a combination of wild-type enzyme and mutant enzyme.

**[0021]** The term "inclusion body" (which also could be denoted "protein inclusion body" or "cytoplasmic inclusion body" means a body formed by aggregation of insoluble polypeptide chains that is found in the cytoplasm of cells. Such inclusion bodies are seen in prokaryotic cells that serve as hosts for recombinantly produced foreign proteins. It is currently believed that the majority of the recombinant proteins in inclusion bodies are misfolded or biologically inactive, though some activity has been seen in recombinantly produced fluorescent proteins. As is apparent from the above, the invention does not relate to recombinant proteins found as inactive inclusion bodies when expressed in a host such as e.g. *E. Coli* and consequently, the invention relates to recombinant enzymes that are expressed and resulting in such a folded state so as to enable enzymatically active forms.

**[0022]** The term "particles", is used herein to describe compositions containing one or more types of an oxalate-reducing enzyme combined with a polymer. In general the term "particles", is used as the broadest term, i.e. without any specific size or shape attribution.

**[0023]** The term "spray-dried particles" mean particles that are obtained by a spray-drying method.

**[0024]** It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise.

#### *Method for isolating and purification of recombinant proteins, notably oxalate degrading enzymes*

**[0025]** The method comprises purifying oxalate reducing enzymes using efficient and simplified steps that result in improved yields of protein.

**[0026]** Recombinant proteins relate to mutated oxalate decarboxylases.

**[0027]** The methods directed to recombinant proteins that are present in the cytoplasm of a host cell as active enzyme proteins, which are not soluble in the cytoplasm and appear to be precipitated, but are not found as inclusion bodies. Such proteins are thought to be insoluble or only slightly soluble in the cytoplasm of the host cell. An aspect comprises lysis of the host cell and facilitated separation of the recombinant protein from the soluble cytoplasmic proteins. Separation may easily be accomplished by centrifugation or filtration of the cytoplasm. After separation, the recombinant protein is preferentially solubilized by methods including, but not limited to, adding binding ligands or altering the pH. Once soluble, the protein can be removed from solution, for example by precipitation, and stored or used, such as in particles disclosed herein.

**[0028]** Methods comprise methods for isolation and purification of recombinant oxalate reducing enzymes, such as mutated recombinant oxalate reducing enzyme proteins. Expression of recombinant proteins often results in the sequestering of the proteins in inclusion bodies in *E. coli* because the proteins in inclusion bodies pose much less of a toxic burden to the host cells than soluble recombinant proteins. The proteins in inclusion bodies are also less accessible to degradation by *E. coli* proteases due to the insoluble form. However, it is quite challenging to refold the proteins from inclusion bodies to yield active enzymes. If a protein can be expressed in an active form, but insoluble or only slightly soluble in *E. coli* cells during expression, and are not found as inclusion bodies, the protein expression could be at levels

like those seen when inclusion bodies are formed. Proteins having limited solubility in the cytoplasm and thus, precipitating in the cytoplasm of the cells, would not require a refolding step.

**[0029]** For example, oxalate decarboxylase (OxDC) wild type recombinant protein has a certain level of solubility in *E. coli* cytoplasm, with a smaller portion (5%, Table 1) found as soluble protein in cell lysate and a larger portion (95%, Table 1) found as insoluble protein in the broken cell pellet. The insoluble portion can dissolve in high salt concentrations such as 1 M NaCl or 0.75 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and the dissolved OxDC contains two major forms which can be separated by a hydrophobic interaction chromatography (HIC) column (Fig. 1). Both OxDC peaks are active, but OxDC in the peak eluted at higher concentrations of salt (peak 1, Fig. 1) shows about 20% higher specific activity. It appears that the OxDC in the peak eluted at lower concentrations of salt (peak 2, see Fig. 1) is damaged. This protein fraction is more hydrophobic and less active. Soluble proteins in the cytoplasm are more accessible to damage by protease hydrolysis, other enzyme catalyzing reactions, chemical reaction and physical modification.

**[0030]** Proteins expressed as Inclusion bodies have been widely reported, but there is no report on how to express a protein in an insoluble or slightly insoluble state, such as precipitated, and in an active form. Having a recombinant protein rendered less soluble in the cytoplasm of the host leads to a simplified purification method for the protein. Because the recombinant protein is insoluble or has lower solubility, the soluble proteins of the host organism, such as *E. coli*, are easily separated by centrifugation or filtration, generally as a first step after lysis of the host cell. The insoluble or slightly soluble recombinant protein, found in the centrifugation pellet or the remainder after filtration, may be treated, such as by solubilization with a selective buffer. A selective buffer is found by selection of pH and/or screening specific binding ligands. Many proteins have very limited solubility when the pH is close to the pI, but have increased solubility when the pH is greater than 2 pH units above or below the pI. Protein solubility may also be changed by suspending the pellet in solutions containing binding ligands. For example, OxDC has limited solubility at pH 4.5-7.8 for the wild type recombinant protein and pH 4.0-8.0 for the C383S mutant protein. C383 indicates the cysteine at amino acid 383 in the oxalate decarboxylase amino acid sequence. The S indicates that the cysteine has been replaced with a serine. OxDC solubility increases if the pH is greater than 8.5 for the wild type OxDC and 9.0 for the C383S mutant. Tris and arginine are selective binding ligands to OxDC, and use of either of them will increase OxDC solubility. Methods comprise purification steps comprising adding binding ligands to aid in solubility of enzymes or proteins found in a pellet after centrifugation, or retentate after filtration, of soluble protein of a host cell.

**[0031]** Moreover, such methods for isolating a mutated oxalate reducing enzyme recombinant protein may result in increased amounts of recovered protein, and higher amounts than those seen with recombinant wild-type oxalate reducing enzyme protein. The methods normally also have fewer steps so that a more simple purification process is possible. For example, the soluble proteins of the host organism, such as *E. coli*, are separated, such as by centrifugation or filtration from the recombinant protein which is insoluble or has lower solubility than the host proteins in the host cell cytoplasm. Mutated oxalate reducing recombinant proteins may not be like the wild-type recombinant protein in other ways, such as the mutated proteins may not form protein-protein interactions that lead to aggregate formations. For example, replacement of the cysteine amino acid in oxalate decarboxylase results in a mutated protein that cannot form disulfide bonds, which leads to fewer to no protein aggregates.

**[0032]** An example of a method of the present invention comprises lysis of host cells that are making recombinant mutated oxalate reducing enzyme protein or proteins. After lysis of the host cells, for example, *E. coli* cells, all soluble host proteins are removed, for example, by filtration or centrifugation. The recombinant protein, such as a mutant recombinant oxalate reducing enzyme protein, which is not soluble or only slightly soluble in the cytoplasm of the host cell, and is not found as an inclusion body, is found in the centrifugation pellet or as retentate in filtration. The mutant protein is then solubilized, such as by solubilization with a selective buffer or a binding ligand, or other methods known to those skilled in the art. A selective buffer may be determined for example, by pH parameters. Many proteins have limited solubility when the pH is close to the pI, but will have increased solubility when the pH is greater than 2 pH units above or below the pI. For example, OxDC has limited solubility at pH 4.5-7.8 for the wild type recombinant protein and pH 4.0-8.0 for the C383S mutant recombinant protein.

**[0033]** Solubilization may also be affected by protein binding ligands. Protein solubility may change when binding ligands are present in solution. This property can be applied to protein purification through selective precipitation and dissolving. Binding ligands for a particular protein can be found by methods known to those skilled in the art, such as differential scanning calorimetry, UV spectroscopy, infrared spectroscopy, fluorescence spectroscopy and other methods which detect ligands and protein interactions. For example, there are a number of chemical compounds and ions that can bind to OxDC and influence solubility such as Tris, arginine, Mn<sup>2+</sup>, Mg<sup>2+</sup>, and Ca<sup>2+</sup>. It is preferable to use compounds or ions that do not inhibit the activity of the enzyme or if the compounds or ions inhibit activity that the compounds or ions are easily removed to recover active enzyme proteins. For example, Tris and arginine do not inhibit OxDC activity and increase OxDC solubility when pH is greater than 8.0 for wild type OxDC and 8.5 for the C383S mutant of OxDC.

**[0034]** Methods for isolation and purification of a mutant recombinant oxalate reducing enzyme protein may comprise one or both of, low solubility of the recombinant mutant protein in host cytoplasm, and high solubility of the mutant recombinant oxalate reducing enzyme protein after changing solubilization conditions by adding binding ligands.

**[0035]** In currently used processes for isolating and purifying recombinant proteins problems often arise in the use of large chromatography columns which are challenging to construct and operate at a scale that is required for large scale isolation and purification. This process is demonstrated in Example 1. Eliminating such steps would lead to a lower cost for purification and a simpler process, which is demonstrated in Example 4.

**[0036]** Methods comprise purification or isolation of a recombinant protein from host cells. Methods of isolation comprise isolating a recombinant protein that is slightly insoluble to insoluble in the cytoplasm of the host organism. Isolation steps comprise obtaining a host cell lysate, washing the lysate, such as by resuspending the lysate and centrifuging it to form a lysate pellet: suspending the lysate pellet in a protein solubilization media that contains binding ligands that alter the pH response of the protein (e.g. increase the solubility of the protein); centrifuging the mixture and acting on the liquid phase, not the non-soluble pellet. The recombinant protein is removed from the liquid phase. For example, the pH of the liquid phase is adjusted and the recombinant protein precipitates out of solution. The non-soluble pellet may be re-extracted multiple times to form liquid phases out of which the recombinant protein is removed, such as by precipitation. The removed protein may be washed one or more times and stored or used as needed.

**[0037]** Enzymes that are insoluble or only slightly soluble in the cytoplasm and are not found as an inclusion body of host cells, such as *E.coli*, and are isolated by the methods taught herein, consist of recombinant mutated oxalate decarboxylases that comprise mutations, comprising, but not limited to, replacements. Such modified enzymes may have more, less or the same activity as native enzymes, or may have characteristics that are the same or different from native or unmodified enzymes. The present invention relates to methods and compositions comprising whole enzymes, sequences and promoter and control sequences of oxalate decarboxylases.

**[0038]** The present invention comprises use of recombinant proteins, and recombinant proteins mutated so as to cause the proteins to be insoluble or only slightly soluble in the cytoplasm of the host at rates higher than those seen in wild-type or not-mutated recombinant proteins. Additionally, these recombinant proteins are not found as inclusion bodies in the host cell. There are several methods to modify protein solubility such as replacement of hydrophilic residue(s) with less hydrophilic residue(s), replacement of charged amino acid(s) with non-charged amino acid(s), and/or addition of hydrophobic peptide tail(s) at the C- and/or N-terminus. The modifications should not inactivate the protein and the modified protein with low solubility should be expressed in an active form by the host cell, such as by *E. coli*.

**[0039]** An example of mutations contemplated by the present invention is described. Both the N- and C-terminals of OxDC are distant from the catalytic sites and are quite flexible. The flexibility of the two termini as determined from x-ray crystallography reveal that the first 7 amino acids of the N-terminal tail and the last 6 amino acids of the C-terminus did not diffract due to conformational heterogeneity. Among the 6 residues at the C-terminus, C383 was chosen for mutation because there are many amino acids more hydrophobic or hydrophilic than Cys which can be selected to replace it. C383 represents the cysteine at position 383 in the oxalate decarboxylase amino acid sequence. In addition, C383 is the only Cys in OxDC, but has been shown to readily form disulfide bonds among OxDC hexamers and further generate aggregates. Replacement of C383 may eliminate formation of such aggregates and thus increase OxDC stability in solution. Mutations were introduced in the C-terminus region.

**[0040]** Multiple genes were created from the original *yvrk* gene sequence (the wild-type *yvrk*), oxalate decarboxylase. The original gene was from *Bacillus subtilis*, and the gene sequence was optimized for expression in *E. coli* using an algorithm from GenScript Corporation, Piscataway, NJ. The gene was optimized for codon usage, balancing GC content, removing repetitive elements, and ensuring the absence of internal restriction sites for cloning. The codon optimized gene resulted in a protein with the identical amino acid sequence as the wild-type *yvrk*.

**[0041]** Modifications were then made to the single cysteine codon of both the wild-type *yvrk* gene, and the optimized *yvrk* gene, resulting in additional unique gene sequences. The cysteine codon was replaced with a serine, arginine, or alanine codon.

**[0042]** The gene sequence of the wild-type *yvrk* gene may be optimized for additional expression systems such as *Pichia* or *Saccharomyces* using the same methods. In addition, expression in a *Bacillus* expression system may be improved by optimizing the gene for optimum codon usage and GC content, and removal of repetitive elements. Codon optimization may also be used for modification of the secondary structure of the protein at positions other than the cysteine codon already modified, or in addition to the cysteine modification, for example, as a method to improve pegylation, microsphere binding or encapsulation, as a method to improve pH stability at low pHs, or as a method to improve the activity of the protein.

SEQ ID 1

Original *yvrk* sequence with the cysteine codon marked in bold.

AAAAAACAAAATGACATTCCGCAGCCAATTAGAGGAGACAAAGGAGCAACGGTAA  
AAATC

5 CCGCGCAATATTGAAAGAGACCGGCAAAACCCTGATATGCTCGTTCCGCCTGAAA  
CCGAT

10 CATGGCACCGTCAGCAATATGAAGTTTTTCATTCTCTGATACTCATAACCGATTAGA  
AAAA

15

20

25

30

35

40

45

50

55



GGCGGATATGCCCGGGAAGTGACAGTACGTGAATTGCCGATTTCAGAAAACCTTG  
 CATCC  
 5 GTAAATATGCGGCTGAAGCCAGGCGCGATTGCGGAGCTTCACTGGCATAAAGAA  
 GCTGAA  
 TGGGCTTATATGATTTACGGAAGTGCAAGAGTCACAATTGTAGATGAAAAAGGGC  
 10 GCAGC  
 TTTATTGACGATGTAGGTGAAGGAGACCTTTGGTACTTCCCGTCAGGCCTGCCGC  
 ACTCC  
 15 ATCCAAGCGCTGGAGGAGGGAGCTGAGTTCCTGCTCGTGTTTGACGATGGATCAT  
 TCTCT  
 GAAAACAGCACGTTCCAGCTGACAGATTGGCTGGCCCACACTCCAAAAGAAGTCA  
 TTGCT  
 20 GCGAACTTCGGCGTGACAAAAGAAGAGATTTCGAATTTGCCTGGCAAAGAAAAAT  
 ATATA  
 TTTGAAAACCAACTTCCTGGCAGTTTAAAAGATGATATTGTGGAAGGGCCGAATGG  
 25 CGAA  
 GTGCCTTATCCATTTACTTACCGCCTTCTTGAACAAGAGCCGATCGAATCTGAGGG  
 AGGA  
 30 AAAGTATACATTGCAGATTGACAACTTCAAAGTGTCTAAAACCATCGCATCAGC  
 GCTC  
 GTAACAGTAGAACCCGGCGCCATGAGAGAACTGCACTGGCACCCGAATACCCAC  
 35 GAATGG  
 CAATACTACATCTCCGGTAAAGCTAGAATGACCGTTTTTGCATCTGACGGCCATGC  
 CAGA  
 40 ACGTTTAATTACCAAGCCGGTGATGTGCGGATATGTACCATTTGCAATGGGTCATTA  
 CGTT  
 GAAAACATCGGGGATGAACCGCTTGTCTTTTGTAGAAATCTTCAAAGACGACCATTA  
 45 TGCT  
 GATGTATCTTTAAACCAATGGCTTGCCATGCTTCCTGAAACATTTGTTCAAGCGCA  
 CCTT  
 50 GACTTGGGCAAAGACTTTACTGATGTGCTTTCAAAGAAAAGCACCCAGTAGTGAA  
 AAAG  
 AAAT**GC**AGTAAA

Yvrk gene sequence optimized for E. coli, with restriction sites at the 5' and 3' ends (underlined), and the cysteine codon marked in bold.

SEQ ID 2

CATATGAAAAAACAGAATGACATTCCACAGCCGATTTCGCGGCGATAAAGGCGCGA  
CCGTC

5 AAAATTCTCGCAATATCGAACGCGACCGCCAGAATCCGGATATGCTGGTGCCGC  
CGGAG

ACGGACCATGGCACGGTGTCTAACATGAAATTCTCTTTTAGCGATACCCACAACC  
10 GCCTG

GAAAAAGGTGGCTACGCGCGCGAGGTTACCGTCCGTGAACTGCCAATTAGCGAA  
AATCTG

15 GCTTCGGTTAACATGCGTCTGAAACCAGGTGCTATCCGTGAGCTGCACTGGCACA  
AGGAA

GCGGAATGGGCGTATATGATTTACGGTTCAGCACGTGTTACCATCGTAGACGAGA  
20 AAGGT

CGTAGCTTTATCGATGATGTTGGCGAAGGTGATCTGTGGTATTTCCCATCTGGCCT  
GCCG

25 CATTCGATTCAGGCGCTGGAAGAAGGCGCTGAATTTCTGCTGGTGTTCGATGATG  
GTTCC

TTTTCTGAAAACAGCACGTTCCAGCTGACGGATTGGCTGGCGCACACGCCGAAAG  
AAGTC

30 ATTGCGGCCAATTTTGGGGTAACCAAAGAAGAAATTTCCAACCTGCCGGGCAAAG  
AAAAG

TATATTTTTGAGAATCAGCTGCCGGGCTCTCTGAAGGACGATATTGTAGAAGGCC  
35 CTAAC

GGTGAGGTGCCGTATCCGTTACCTATCGTCTGCTGGAGCAGGAACCGATTGAAA  
GCGAA

40 GGCGGTAAAGTTTATATCGCAGATTCCACTAACTTTAAAGTCTCCAAGACCATTGC  
CAGC

GCCCTGGTCACCGTGGAACCGGGAGCGATGCGCGAGCTGCACTGGCATCCGAA  
45 CACGCAC

GAATGGCAGTATTATATTTCCGGCAAAGCACGCATGACCGTTTTTGCCTCAGATG  
GACAC

50 GCTCGCACGTTTAATTATCAAGCGGGTGATGTTGGCTACGTTCTTTGCCATGG  
GCCAT

TATGTAGAAAATATCGGCGATGAACCACTGGTGTCTTCTGGAGATCTTTAAAGATGA  
55 CCAC

TATGCCGATGTTTCACTGAATCAGTGGCTGGCCATGCTGCCGGAAACTTTTGTTCAGGCCG  
 CATCTGGACCTGGGTAAAGACTTTACGGATGTGCTGAGCAAAGAAAAACACCCGG  
 TAGTCAAGAAGAAATGCAGTAAAGGATCC

**[0043]** Other sequences of the present invention comprise the yvrk gene of SEQ ID 1 comprising bases 1142-1152 of SEQ ID 3-8, 15-19. NOs 3-8 are serine, and NOs 15-19 are alanine.

SEQ ID 3 ATCTAGTAAA	
SEQ ID 4 ATCCAGTAAA	
SEQ ID 5 ATCAAGTAAA	
SEQ ID 6 ATCGAGTAAA	SEQ ID 15 AGCTAGTAAA
SEQ ID 7 AAGTAGTAAA	SEQ ID 16 AGCCAGTAAA
SEQ ID 8 AAGCAGTAAA	SEQ ID 17 AGCAAGTAAA
	SEQ ID 18 AGCGAGTAAA
	SEQ ID 19 AGGAAGTAAA

#### *Spray-dried particles*

**[0044]** The present invention relates to spray-dried particles comprising one or more recombinant proteins selected from the group consisting of the C383S, and the C383A mutant of the oxalate decarboxylase (OxDC) wild type recombinant protein according to SEQ. ID NO. 1 or SEQ. ID NO. 2, or a protein encoded by a sequence selected from SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18, or SEQ. ID NO. 19; and a polymeric material, wherein said proteins are prepared as nano- or micro-agglomerates.

**[0045]** The particles should be able to degrade oxalate in the stomach of a human or animal, i.e. formation of the particles may not lead to marked loss of activity of the enzymatic activity and the properties of the particles must be to protect the enzymes contained in the particles from degradation and/or inactivation. Thus, the enzyme must be active at a pH corresponding to the pH normally found in the stomach (pH 2.5-5 after meal) or, alternatively, a pH-regulating agent may be incorporated in the particles as well or admixed with the particles before administration. Suitable pH-regulating agents include buffer substances such as those well known to the skilled person.

**[0046]** Particle formation (in combination with the use of a specific method for preparing the particles and specific polymers or copolymers employed) is contemplated to protect the enzyme protein from pepsin digestion to ensure activity of enzyme. Particle formation of proteins and polymeric material is contemplated by the present invention. As used herein, particle formation means the association of protein with a polymeric or copolymeric solution to form small particles comprising active enzymes and polymers or co-polymers. Such methods of formation of active enzyme particles increase the amount of active enzyme in the particle and may increase the efficacy of a dosage form containing the particles when used in a treatment or prevention regimen. The particle formation aids in the protection of the enzyme from pepsin digestion.

**[0047]** It is important to ensure that the method employed for particle formation does not involve reagents, solvents, temperatures, apparatus etc. that leads to a risk for inactivation of the enzymes. Thus, care should be taken to avoid methods involving e.g. organic solvents, high temperatures and low or high pH.

**[0048]** There are many approaches to particle formation such as coacervation, phase separation, polymerization, spray-drying, electrostatic methods, and air suspension approaches. Spray drying is a mechanical micro-encapsulation method developed in the 1930s. This technique utilizes a drug or active substance, mixed with polymer(s) and/or other excipients to form the feed, which can be either a solution, suspension, dispersion, or emulsion. The feed is atomized into droplets and introduced in the drying chamber along with dry hot gas. Droplets lose moisture to the dry hot gas and form dry powders.

**[0049]** A suitable method for making active enzyme particles of the present invention is spray-drying. In such a method the enzyme(s) and polymer(s) are dispersed or dissolved in an aqueous medium and via a nozzle loaded into a suitable spray-drying apparatus. The conditions are mild, even if a relatively high inlet and outlet temperatures are employed, the examples herein show that the activity of the enzyme(s) contained in the particles remain at a high level, and even

higher levels have been observed. Other methods may also be of relevance provided that the activity of the enzyme(s) is not seriously destroyed (at least 80% of the activity should be maintained). With respect to spray-drying, the examples herein show a remaining activity of at least 85% and remaining activities of at least 90% and at least 100% are also seen.

**[0050]** In many particle formation methods, the protein is usually provided in a solution. Normally, the proteins in a particle are distributed homogeneously, which leads to difficulties in achieving an effective concentration of the enzyme inside the particles to provide an adequate or increased level of enzyme activity. In a spray-drying method the protein may be provided in solution or in dispersion or suspension, where the enzyme protein is in a solid state, for example, as an enzyme protein nano- or micro-agglomeration. When the particles are provided to the intended delivery site, the solid enzyme nano- or micro-agglomeration in the particles is solvated and forms an effective concentration of an enzyme solution. The enzyme concentration may be at a level such that the specific activity increases. For example, the C383S mutant of OxDC only minimally dissolves in buffers between pH 4.5-7.8, and it can be prepared as a protein nano- or micro-agglomeration in a water suspension at pH 4.5-7.8. The C383S nano- or micro-agglomeration suspension then is mixed with a polymer solution or suspension, and particles are formed by spray drying or other drying technologies. The concentration of the C383S mutant OxDC in the particles shows a specific activity of the C383S mutant of up to 141% of its original specific activity. Thus, spray-drying is the preferred method for making the particles.

**[0051]** In the non-limiting examples herein are described methods of how to combine the enzyme in a polymeric material. A person skilled in the art may find other methods suitable for use in order to prepare a composition according to the present invention. By incorporation of the enzyme in a polymeric material, the enzyme obtains a certain protection against conditions similar to gastric fluid with respect to pH and pepsin. The resulting oxalate reducing enzyme composition appears as particles, i.e. discrete units in micron- or nano-size.

**[0052]** Normally, the particles of a composition of the invention have an average diameter of from about 50 nm to about 1 mm, such as, e.g., from about 500 nm to about 500  $\mu\text{m}$ , from about 1  $\mu\text{m}$  to about 500  $\mu\text{m}$ , from about 2  $\mu\text{m}$  to about 100  $\mu\text{m}$ , from about 4  $\mu\text{m}$  to about 80  $\mu\text{m}$ , from about 6  $\mu\text{m}$  to about 60  $\mu\text{m}$ , from about 8  $\mu\text{m}$  to about 40  $\mu\text{m}$ , from about 10  $\mu\text{m}$  to about 20  $\mu\text{m}$ .

**[0053]** Many different polymers and copolymers may be suitable for particle formation such as natural or synthetic polymers including but not limited to, alginate, dextran, cellulose, collagen, chitosan, alginate, pectin, hyaluronic acid, PLGA, polyvinyl alcohol (PVA), poly(acrylic acid), poly(lactic acid), poly(ethylene glycol), poly(esters), etc.

**[0054]** However, in the present context Eudragit® polymers have been found to lead to the desired result, i.e. maintaining a suitable activity of the enzyme and sufficient protection of the enzyme from pepsin or other enzymes present in the stomach as well as the low pH of the content of the stomach.

**[0055]** Eudragit® polymers are polymers based on poly(meth)acrylates and are available in a number of varieties e.g. for gastroresistance and GI targeting, for moisture protection and odor/taste masking, for time-controlled drug release. Some Eudragit® polymers (Eudragit® series L, S and FS) have different solubility in acidic and neutral/alkaline environment and pH-cut off (i.e. the value at which the polymer becomes soluble) varies from 5.5 to >7. Other Eudragit® polymers (series E and EPO) are soluble in gastric fluid up to pH 5 and swellable at higher pH values. Some Eudragit® polymers (series RL, RS, NE and NM) are insoluble and have a pH independent swelling.

**[0056]** As seen from the examples herein, Eudragit® polymers of the first and third group mentioned above are suitable for use in the particles of the present invention. In the first group that includes Eudragit® L100-55, L30-55, L100, L12.5, S100, S12.5, and FS30D the polymer is a methacrylic copolymers with a carboxylic acid as a functional group, i.e. the polymer is an anionic polymer. In the second group that includes Eudragit® E100, E12.5 and EPO, the polymer is aminoalkyl methacrylate copolymers with dimethyl aminoethyl as a functional group. In the last group that includes Eudragit® RL30, RL PO, RL100, RL12.5, RS30D, RS PO, RS100, RS12.5, NE 30D, NE40D, NM30D, the polymer is aminoalkyl methacrylate copolymers with trimethyl-ammonioethyl-methacrylates as a functional group (series RL and RS) or the polymer is neutral polymers of methacrylates (series NE and NM). The polymers are available from Evonik Industries.

**[0057]** The concentration of the polymer in the particles is from about 5 to about 80% w/w such as from about 5 to about 70% w/w, from about 5 to about 60% w/w, from about 5 to about 50% w/w, from about 10 to about 50% w/w or from about 10 to about 40% w/w.

**[0058]** In the examples herein, suitable particles have been formed using Eudragit® L-100, L-100-55, RS, RL, i.e. representing group one and three above.

**[0059]** The composition that is spray-dried may apart from the enzyme and the polymeric material also contain one or more excipients or additives. Excipients can be any molecules that protect the enzyme from heat, dehydration and storage such as sugars, amino acids, surfactants, salt, etc. Pharmaceutically acceptable excipients like those described herein may also be employed.

**[0060]** The particles may be formed by known methods, preferably by spray-drying. After forming the particles comprising one or more enzymes and a polymeric material, the particles may be further treated, such as by drying, freeze-drying or lyophilization. Although freeze-drying does not generate particle formation, it can dry already formed particles comprising enzymes and polymeric material. The particles can be in a state of suspension, dispersion, or emulsion,

which are then subjected to freeze dry conditions. Freeze-drying avoids heating the enzymes and makes the drying process suitable for heat sensitive proteins. Freeze-drying or other methods (e.g. coating) may be omitted and then particles of polymer and oxalate reducing enzymes are formed solely by spray drying. Such particles may then be formulated into oral pharmaceutical or food formulations such as by mixing with bulking agent and e.g. filling in sachets, adding the particles to capsules, compressing the particles into tablets, incorporating the particles in chewable tablets, incorporating the particles into quick dissolve or oral dissolve tablets, or adding particles to liquids, syrups, elixirs or foodstuffs.

**[0061]** For example, particles were made by combining oxalate decarboxylase (OxDC) with a polymeric material, Eudragit L100. For comparison, OxDC was lyophilized with arginine buffer only. Both the lyophilized enzyme, without polymeric material and the particles formed by spray-drying the combination of OxDC with Eudragit L100, followed by freeze-drying, resulted in 100% recovery yields and no loss of activity. The particles comprising OxDC with Eudragit L100 were protected from pepsin degradation in solutions from pH 3.25 to pH 5.0 for at least 40 minutes, for at least 60 minutes, for at least 90 minutes, for at least 120 minutes.

**[0062]** The present invention comprises particles of oxalate reducing enzymes, mutated, and a polymeric material which protects the enzymes from degradation under gastric conditions (pepsin). The present invention contemplates compositions that comprises oxalate decarboxylase, and such enzymes may be non-native or mutated enzymes having mutations, modifications or alterations in nucleic acid sequence, amino acid sequence, binding groups, carbohydrates, or lipids. These enzymes use oxalate as a substrate or are active in a step in oxalate metabolism or catabolism.

**[0063]** Thus, the particles of the invention protect the oxalate-degrading enzyme from the gastrointestinal environment. Furthermore, the particles of the invention do not substantially release the enzyme to the gastrointestinal environment. In other words, the enzyme remains in the particle after oral administration for a sufficient period of time to enable oxalate in the stomach to be degraded or reduced. The enzymes may be released from the particles while in the stomach or after leaving the stomach, depending on the type of polymer used to make the particle or on treatments to the particle, such as coating or cross-linking. In the particles the polymeric material may function as a protective carrier for the enzyme and at the same time may allow the substrate, i.e. oxalate, to diffuse or otherwise be transported into the composition to enable an *in situ* degradation of oxalate. A feature of the particles of the present invention is their ability to retain the enzymatic activity for a period of time longer than that observed for an enzyme that is not in the form of such particles, especially in the presence of pepsin. Accordingly, one aspect the present invention relates to particles comprising one or more oxalate reducing enzymes and a polymeric material, wherein the enzyme retains at least two times the activity of the one or more free enzymes (i.e. not in the form of such particles), obtained from the same batch, upon incubation a buffer containing 3.2 mg/ml pepsin at pH 3.25 at 37°C for at least 60 minutes. It is important that the test conditions for the particles according to the invention and the free enzymes are the same, for example, with respect to the nature and purity of the enzyme, the initial concentration of the enzyme, the test volume, the composition of the incubation medium (e.g. the buffer), the temperature, etc.

**[0064]** Normally, the enzyme contained in the particles retains at least three times the activity, at least four times the activity, or at least five times the activity of the one or more free enzymes obtained from the same batch upon incubation in a buffer containing 3.2 mg/ml pepsin at pH 3.25 at 37°C for at least 30 minutes, at least 45 min, at least 60 minutes, at least 75 minutes, at least 90 minutes, at least 105 minutes or at least 120 minutes.

**[0065]** In a specific embodiment, the one or more oxalate reducing enzymes in the particles of the invention retain at least two times, at least 10 times, at least 50 times or at least 100 times, the activity of the one or more free enzyme, obtained from the same batch, upon incubation in a buffer containing 3.2 mg/ml pepsin at pH 3.25 at 37°C for at least 60 minutes.

**[0066]** Suitable buffer substances for providing a buffer solution having a specific pH are known to persons skilled in the art. Examples are glycine buffers, acetate buffers, phosphate buffers, borate buffers and the like. The buffer solution may contain additional ingredients such as e.g. inorganic salt in order to adjust the ionic strength of the buffer solution, or one or more proteases like e.g. pepsin in order to ensure that the conditions in the buffer solutions challenge whether the embedded enzyme can withstand such harsh conditions.

**[0067]** Other polymers may also be present in the particles together with one or more poly(meth)acrylate polymer. Such polymers include, but are not limited to, man-made or natural polymers, including, but not limited to, i) a polysaccharide: alginate including alginic acid, alginate e.g. sodium alginate, potassium alginate, ammonium alginate, calcium alginate, propane-1,2-diol alginate, acacia, carrageenan, chitosan and its derivatives, chondroitin sulfate, dextran derivatives, heparin, hyaluronic acid, inulin, a cellulose or a cellulose derivative including methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylmethylcellulose, or the like or combinations thereof; ii) a mucopolysaccharide, iii) a gum including locust bean gum, guar gum, tragacanth, agar, acacia gum, xanthan gum, karaya gum, tara gum, gellan gum, or the like or combinations thereof; iv) a gelling- or swelling agent including hydrocolloids and hydrogelling agents such as, agar, carrageenan, gelatin, polyvinylpyrrolidone, or the like, or combinations thereof; v) others like e.g. protein and polyamide: collagen, albumin, protamine, spermine, synthetic polymer: poly (acrylic acid), polyphosphoric acid, tripolyphosphate, poly (L-lactic acid), poly (vinyl alcohol),

poly (DL-lactic acid-co-glycolic acid), Eudragit polymers, including but not limited to L-100, L-100-55, RS, RL, or copolymers or mixtures and combinations thereof. In an embodiment, the polymeric material is Eudragit polymers, including but not limited to L-100, L-100-55, RS or RL.

**[0068]** Other polymeric materials that may be added to the poly(meth)acrylate polymer formulation may be biopolymers or synthetic polymers. Examples of biopolymers include, but are not limited to, proteins, polysaccharides, mucopolysaccharides, heparin, heparin sulfate, heparinoids, dermatan sulfate, pentosan polysulfate, chondroitin sulfate, cellulose, agarose, chitin, carrageenin, linoleic acid, and allantoin, cross-linked collagen, fibronectin, laminin, elastin, cross-linked elastin, collagen, gelatin, hyaluronic acid, chitosan alginate, dextran, methylcellulose, polylysine, and natural rubber. In the compositions of the present invention wherein polymeric matrices are formed, these matrices are porous such that small water soluble molecules can enter and exit the polymeric matrix, including, but not limited to molecules such as oxalate, formic acid, formate, carbon dioxide, oxygen, or oxalyl-CoA. A concentration of the polymeric material in a composition of the invention is normally in a range from 10% to 90% of the total dry materials

**[0069]** In addition to the one or more enzymes and a polymeric material, the particles may also contain one or more additives such as, e.g., pH adjusting agents, buffering agents, solubilizing agents, stabilizers, preservatives, cofactors for the enzymes or one or more pharmaceutically acceptable excipients such as, e.g. fillers, bulking agents, diluents, carriers or the like.

**[0070]** Moreover, it may be advantageous to create a localized acidic pH environment around a protein when the physiological conditions result in a pH well below the reasonable working range of the enzyme. For example, in a lower pH location, an oxalate reducing protein with maximum activity at pH 4 would benefit from a delivery vehicle capable of increasing the local pH in the proximity around the enzyme to around pH 4.

**[0071]** In addition, it may be desirable to include a buffer in the delivery vehicle in the form of a base, base containing or base generating material that works in conjunction with the in vivo pH, or the localized pH, or a combination of both to optimize/control the local pH around the enzyme. These buffers may include salts of organic or inorganic compounds or a number of other buffers. It is understood that the pKa of the conjugate acids of which the buffering materials are associated/derived from can be utilized in the appropriate selection of buffering materials.

**[0072]** In some case a polymeric material may be applied to the particles (e.g. as a coating) in order to increase the shelf stability of the particles or to inhibit a degradation of the enzyme. Such polymeric material may, if relevant, moreover be cross-linked. The cross-linking may be by physical or chemical cross-linking. Physical cross-linking may comprise opposite charged polymers cross-linked with each other by salt bonds (for example: chitosan, which is positively charged, cross-links with tripolyphosphate or heparin, which are negatively charged polymers), charged polymers cross-link with opposite charged ions (for example: alginate with  $\text{Ca}^{2+}$ , carboxymethyl-cellulose with  $\text{Al}^{3+}$ ). The term "physical cross-linking" used in the present context also includes noncovalent bindings and/or interactions.

**[0073]** Chemical cross-linking generally comprises cross linking by cross-linkers with two reactive functional groups such as by polymer bearing amine groups such as proteins, polyamide, chitosan and its derivatives, may be cross-linked through glutaraldehyde or genipin. UV irradiation can be used to induce polymers bearing light sensitive groups to form covalent cross-links.

**[0074]** The properties of the particles, for examples: micro-environmental buffer capacity, mechanical strength, particle size, oxalate diffusion rate, interactions with enzymes, largely depend on selected polymer(s), polymer composition and ratio, optional cross-linking methods and preparation procedures.

**[0075]** The particles may also be provided with a coating. Such a coating has generally the same function as the polymeric material, i.e. to avoid a substantial decrease in the enzymatic activity of the enzyme embedded in the polymer during storage and/or after oral administration.

**[0076]** Suitable coating materials are such materials that allow an aqueous composition containing oxalate to diffuse into, or otherwise enter, the particle of the invention. As mentioned above, the substrate (i.e. the oxalate-containing medium) enters into the particle composition of the invention so that enzymatic degradation of oxalate can occur. Accordingly, coating materials resulting in either diffusion coating or otherwise permeable coatings (e.g. coatings containing pore-forming substances that are substantially water-soluble) can be applied.

**[0077]** Examples of suitable coating materials include, but are not limited to, the materials contemplated as the polymeric materials. A coating material may be chosen that is different than that used as the polymeric material, but the polymeric material and the coating material may also be the same. Specific examples of coating materials are film-forming agents such as, e.g. polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxyethylcellulose, hydroxypropylcellulose, polydextrose, maltodextrin, or other polysaccharides including chitosan, alginates and hyaluronic acid. If present, the coating material is normally applied in such an amount the weight gain of the particles is at the most about 40%.

## Compositions

**[0078]** In order to deliver the particles as described above to the stomach of a human or an animal, the particles may be formulated into a suitable dosage form for oral administration.

**[0079]** Oral formulations include, but are not limited to, capsules, tablets, chewable tablets, quick dissolve tablets, oral dissolve tablets, liquids, and other known oral formulations suitable for pharmaceutical or food use.

**[0080]** A composition of the invention is suitable for use for oral administration to a subject. A composition is provided as oral pharmaceutical formulations, which may be delivered to the oral cavity, the mouth, a buccal patch, to the stomach, attached to the stomach mucosa, in a slow release liquid, in a quick release tablet in the mouth or stomach, coating the esophagus, in a liquid or solid form accompanying food, prior to ingesting food, or immediately after ingesting food.

**[0081]** Compositions of the present invention reduce dietary oxalate under gastric conditions, such as those found after consumption of food, such as in the presence of proteases. Compositions of the present invention reduce oxalate in the stomach of humans and other animals. Compositions reduce oxalate, e.g. oxalate in the gastrointestinal tract, notably in the stomach, and prevent at least a portion of exogenous oxalate (e.g. from food) from entering the systemic circulation.

**[0082]** A composition of the present invention comprises particles as described above. The particles comprises one or more oxalate reducing enzymes and a polymeric material; or particles comprising other enzymes, cofactors and co-enzymes related to oxalate degradation pathways combined with a polymeric material, or both particles, provided separately or together in an oral dose form.

**[0083]** Such compositions comprising particles comprising other enzymes, co-factors, or co-enzymes alone may be administered simultaneously with, sequentially with, or before or after, administration of compositions of particles comprising oxalate reducing enzymes. The compositions comprising particles comprising other enzymes, co-factors, or co-enzymes alone may be combined with compositions comprising particles comprising oxalate reducing enzymes to form a single administrative dose to provide an effective amount of oxalate reduction in the gastric tract.

**[0084]** Compositions may comprise oxalate reducing enzymes that are recombinant proteins that are non-native, mutated oxalate reducing enzymes that have nucleic acid or protein mutations. For example, a non-native oxalate reducing enzyme, oxalate decarboxylase, may have one or more amino acid replacements. The enzymes are described in detail herein.

**[0085]** A composition of the present invention comprises particles comprising mutated recombinant oxalate reducing enzyme proteins and a polymeric material wherein the specific activity of the mutated recombinant oxalate reducing enzyme is higher in the particle than the specific activity of the protein free in solution. Such particles may be administered in compositions such as oral formulations e.g. pharmaceutical or food formulations.

**[0086]** Formulations include, but are not limited to, sachets, tablets, capsules, quick dissolve tablets, oral dissolving tablets, chewable tablets, powders, granules, pellets, liquids, syrups, elixirs, or other oral dosage formulations known to those skilled in the pharmaceutical art. The oral formulations optionally may comprise buffering capabilities. For example, a composition may comprise buffering compounds that adjust the pH of the composition and thus the surrounding environment, such as the stomach once the composition is ingested, to about pH 4. With the environment of the enzyme at pH 4, the enzymes of the present invention are active and reduce oxalate. Such buffer compounds may be acetate, citrate, phosphate or other buffer compounds. A feature of a composition of the present invention is the ability of the particle to protect the oxalate-degrading enzymes from degradation by conditions such as those found in the gastric environment including, but not limited to, degradation by a protease such as pepsin.

**[0087]** The compositions of the present invention may also comprise one or more additional factors which may improve the enzyme activity. These additional factors may be, e.g., oxalyl CoA,  $MgCl_2$ , and/or thiamine diphosphate (an active form of vitamin B<sub>1</sub>), or pH buffering compounds.

**[0088]** The composition administered is normally in solid form e.g. in the form of powders or in a solid dosage form e.g. in the form of sachets, capsules or tablets (e.g. the particles are further processed into a suitable dosage form by methods well-known by a person skilled in the art). To this end, suitable pharmaceutically acceptable excipients may be added such as, e.g., fillers, binders, disintegrants, colors, flavors, pH-adjusting agents, stabilizers etc. Moreover, one or more further therapeutically and/or prophylactically substances may be added and/or other enzymes, cofactors, substrates, coenzymes, minerals and other agents that are helpful in the reduction of oxalate.

**[0089]** Examples of suitable pharmaceutically acceptable excipients include: dextrans, maltodextrins, dextrose, fructose, glucose, lactose, cellulose derivatives including carboxymethylcellulose calcium, carboxymethylcellulose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose (HPMC), microcrystalline cellulose (e.g., various grades of Avicel®), starches or modified starches (e.g. potato starch, maize starch, rice starch, pre-gelatinised starch), polyvinyl acetate, polyvinylpyrrolidone, agar, sodium alginate, sodium croscarmellose, calcium hydrogen phosphate, calcium phosphate (e.g. basic calcium phosphate, calcium hydrogen phosphate), calcium sulphate, carboxyalkylcellulose, dextrates, dibasic calcium phosphate, gelatine, gummi arabicum, hydroxypropyl cellulose, hydroxypropylmethylcellulose, methylcellulose, polyethylene glycol, polyethylene oxide, and as lubricants: talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils and the like.

**[0090]** The compositions of the present invention are suitable for use reducing oxalate levels in humans or animals. They may also be suitable for treating or preventing oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease

(urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.

**[0091]** An oxalate-degrading particle or composition of the invention is administered in a desired amount, such as an amount that is sufficient to degrade substantially all oxalate normally present in a standard meal. Depending on the food choices, an average Western diet can contain 100 to 300 mg of oxalate/day. In general, about 0.2g of the particles comprising an oxalate reducing enzyme (equal to 50 mg of OxDC in 1 mL of suspension of particles) can degrade about 300 mg oxalate in less than 30 min in simulated gastric conditions. Typical simulated gastric conditions were generated as: 100 ml of USP simulated gastric juice mixing with 400 grams of balanced western style meal (broken into small pieces) and 500 grams of water, yielding pH in the range of 3.5-4.5. Reduction of oxalate absorption may be shown by a reduction in oxalate levels found in the blood, serum or urine, or other body fluids.

**[0092]** An effective amount comprises an amount of activity units of oxalate-reducing enzyme activity that will reduce a portion of the oxalate present, or a level of activity units of oxalate-reducing enzyme activity that will initiate a reduction in the amount of oxalate or maintain a lowered amount of oxalate in the individual, compared to the amount of oxalate present before administration of the composition. The number of activity units of oxalate-reducing enzyme activity that can be used in a single dose composition normally ranges from about 0.001 units to about 20,000 units, from 0.01 to 15,000 units, from 0.1 to 10,000 units, from 1 to 5000 units, from 10 to 4000 units, from 50 to 3,000 units or from 100 to 2,500 units. In those cases where low doses are required the range may be from about 5 units to 100 units, from 0.05 to 50 units, to 0.5 to 500, from about 0.01 units to about 50 units, from about 0.01 units to about 5 units, from about 1 unit to about 100 units, from about 25 units to about 50 units, from about 30 units to about 100 units, from about 40 units to about 120 units, from about 60 units to about 15 from about 50 units to about 100 units, from about 100 units to about 500 units, from about 100 units to about 300 units, from about 100 units to about 400 units, from about 100 units to about 5,000 units, from about 1,000 units to about 5,000 units, from about 2,500 units to about 5,000 units, from about 0.001 units to about 2,000 units and all ranges encompassed therein. A unit of the enzyme is the amount of enzyme that will degrade one micromole of oxalate per minute at 37°C.

#### *Use of particles and compositions*

**[0093]** The particles and compositions of the present invention are suitable in methods of reducing oxalate absorption in the body and are used in the treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.

**[0094]** A reduction in oxalate absorption may be achieved by providing oxalate-degrading enzymes to the gastrointestinal tract, particularly the stomach, thus lowering the concentration of available oxalate for absorption. Reduction of oxalate in the stomach will also reduce the amount of oxalate going into the intestine for absorption in this segment of the gastrointestinal tract. In addition to absorptive pathways, oxalate secretory pathways have been recently identified in the human stomach. The compositions of the present invention would also be useful in degrading the oxalate secreted into the stomach from the circulatory system, and thus the present invention contemplate an overall reduction of the oxalate load in an individual.

**[0095]** The reduction may be measured in any tissue or body fluid environment of the subject. Body fluids include secretions of the body such as nasal or gastric secretions, saliva, blood, serum, urine, chyme or digestive matter, tissue fluid, and other fluid or semi-solid materials made by humans or animals. Particle compositions of the present invention may be mixed in liquids, food or other dietary materials and provided to a human or animal so that the oxalate-reducing enzyme activity of the particles is effective in the stomach environment. Particle compositions of the present invention may also be mixed with foodstuffs or other materials in which oxalate is found and the oxalate-reducing enzyme activity of the particles reduces the oxalate present in the foodstuff or other materials.

**[0096]** The present invention relates to compositions comprising spray-dried particles comprising an effective amount of a C383S or a C383A mutant of the oxalate decarboxylase (OxDC) wild type recombinant protein according to SEQ. ID NO. 1 or SEQ. ID NO. 2, or a protein encoded by a sequence selected from SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18, or SEQ. ID NO. 19; and a polymeric material, for use in a method for treatment of a human or animal subject by reducing oxalate present in the stomach thereby reducing the absorption of said oxalate, said method comprising orally administering the composition to the stomach of the human or animal subject. An effective amount comprises an amount of activity units of oxalate decarboxylase activity that will reduce a portion of the oxalate present, or a level of activity units of oxalate decarboxylase activity that will initiate a reduction in the amount of oxalate present in a meal or present in the tissues or bodily fluids of the subject or maintain a lowered amount of oxalate in the subject compared to



the amount of oxalate present before administration of the composition.

**[0097]** For use in a method for treatment an effective amount of a particle composition as taught herein is administered orally to be ingested by a subject at least once a day, at least twice a day, at least three times a day, at least four times a day or more if necessary, and such administration can be for one day, two days, three days, four days, five days, or a week, two weeks, three weeks, or a month, two months, three months, four months, five months, six months, more than six months, one year, two years, or for years or continuously through the life of the patient. Such treatment may be continued to maintain the desired oxalate levels in a subject.

**[0098]** All patents, patent applications and references included herein are specifically incorporated by reference in their entireties.

**[0099]** The present invention is further illustrated by way of the examples contained herein, which are provided for clarity of understanding. The exemplary embodiments should not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that changes can be made to various other embodiments, modifications, and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the scope of the appended claims.

## Examples

### Methods

#### Assay for enzymatic activity

**[0100]** Oxalate decarboxylase activity is quantified by determining the rate of formate formation. An activity mixture (390  $\mu$ l) containing 40 mM oxalate in 40 mM citric acid, pH 4.0, is incubated at 37 °C for 5 min and the reaction is initiated by the addition of 10  $\mu$ l of an OxDC solution containing 0.2-1 mg/ml of OxDC. After 10 minutes of reaction time, 100  $\mu$ l of 0.5 M H<sub>2</sub>SO<sub>4</sub> is added to quench the reaction. After centrifugation at 14000 g for 10 min, the supernatant is analyzed by HPLC.

**[0101]** All HPLC analyses are performed using an Agilent 1100 Series system. Separations are at 40 °C on an Aminex HPX-87H (Bio-Rad) strong ion exchange column (300 x 7.8 mm ID), protected with an Aminex Cation H Micro-Guard cartridge (Bio-Rad) placed outside the heater. The mobile phase for all analyses is 5 mM H<sub>2</sub>SO<sub>4</sub> (reagent grade (Sigma)) with a flow rate of 0.6 ml/min. Injection volume is 40  $\mu$ l. Detection is at 210 nm and quantification is by formate peak area.

**[0102]** One unit of activity is defined as the amount of OxDC that produces one micromole of formate from oxalate in one minute under the above conditions, or a unit of the enzyme is the amount of enzyme that will degrade one micromole of oxalate per minute at 37°C.

#### Stability test

**[0103]** After incubation of OxDC free enzyme or the composition in question containing the OxDC enzyme embedded in a polymeric material in 100 mM glycine buffer at pH 3.25 containing 3.2 mg/ml of pepsin for a certain period, the remaining OxDC activity was analyzed.

### Example 1

#### A process for production of oxalate decarboxylase from *Bacillus subtilis* by *E. coli*

##### Cloning of *YvrK* gene and optimization of gene codons for higher expression

**[0104]** OxDC from *Bacillus subtilis* is a homohexameric enzyme. Each monomer contains 385 amino acids, with a molecular weight of approximately 44 kDa. The OxDC gene, known as *YvrK*, was PCR-amplified from *B. subtilis* genomic DNA and inserted into the pET9a plasmid (Novagen, catalog # 69431-3) by way of NdeI and BamHI restriction sites.

**[0105]** The *YvrK* gene was codon optimized by Genscript Corp (Boston, MA). Some codons in the original gene sequence were changed to *E. coli* preferred codons in order to increase protein expression. The *E. coli* optimized gene was inserted back into a pET-9a vector through NdeI and BamHI restriction sites to generate pET-9a: *YvrK* and the sequence of the *E. coli* codon optimized gene was confirmed by DNA sequencing. The plasmid with the condon optimized gene was then transformed into *E. coli*. BL21(DE3) for OxDC production by induction with Isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG).

Expression of oxalate decarboxylase (OxDC) in *E. coli* (fermentation)

**[0106]** Expression of OxDC in *E. coli* BL21(DE3) was conducted at 3 different scales of fermentation: 0.4, 50 and 1000 L (liters) of media. In general, the fermentation process was initiated by inoculating the culture media with a seed culture (0.1% inoculum) of bacteria at 37 °C with shaking or agitation. IPTG was added to the culture to induce OxDC expression when OD<sub>600</sub> = 1.0-2.0. After induction, *E. coli* cells were harvested by centrifugation (less than 1000 L scale) or filtration using hollow fiber filters approximately 8-10 hours after induction (1000L).

Purification of oxalate decarboxylase (OxDC) from *E. coli* cells

**[0107]** Lysis of *E. coli* cells and collecting insoluble cell debris containing OxDC. The collected *E. coli* cells were lysed by homogenization, and the cell debris containing OxDC was collected by centrifugation. The cell debris pellet was first suspended in deionized (DI) H<sub>2</sub>O with a weight ratio of H<sub>2</sub>O to pellet of 3:1 to remove any remaining water soluble proteins and other *E. coli* cell components. The washed cell debris was collected again by centrifugation. Approximately 10 grams of cell debris pellet was obtained from 1.0 L of culture, which contained 40-200 mg of OxDC.

**[0108]** Extraction of OxDC by high concentration of (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. The washed cell debris was re-suspended in 3 times by weight of 50 mM Tris HCl buffer, pH 8.0 containing 0.75 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> for extraction of OxDC. The suspension was stirred at 20-25 °C for 30 minutes and the extracted OxDC was collected by centrifugation. Approximately 60% of the expressed OxDC was usually extracted from the pellet by this method.

**[0109]** Anion exchange chromatography column. The extract was diluted 3 times with 50 mM Tris HCl, pH 8.0 and then passed through a Q-sepharose column which was pre-equilibrated with 50 mM Tris HCl, pH 8.0 containing 0.25 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. DNA and other impurities bound to the column while OxDC passes through and collected.

**[0110]** Hydrophobic interaction chromatography column with a gradient evolution. The (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> concentration in the OxDC solution collected from the Q-sepharose column was adjusted to 2.0 M by addition of solid (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> and was loaded into a pre-equilibrated phenyl-sepharose column. OxDC was eluted by way of an (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> gradient. OxDC was eluted into two main peaks at 1.3 M and 0.9 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> respectively (Fig. 1). The peak at 1.3 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> contained approximately 70% of the total OxDC and had a higher purity (>95%). OxDC from this peak was usually selected for the next step.

**[0111]** G-25 column for desalting. OxDC collected from the peak at 1.3 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> was loaded onto a G-25 sepharose containing column for desalting. Approximately 30 mg of purified OxDC was normally obtained from 10 grams of cell debris.

## Example 2

## Modification of OxDC solubility to increase expression level

**[0112]** The C383R mutant oxalate decarboxylase included in this example is not part of the invention.

**[0113]** OxDC has limited solubility at pH 4.5-7.8. The pH of *E. coli* cytoplasm is close to 7.6; thus, OxDC solubility in *E. coli* cytoplasm is very limited. In fact, it is observed that most OxDC expressed by *E. coli* is found in the lysed pellet rather than the supernatant.

**[0114]** Among the last 6 amino acid residues (residues 380-385) at the C-terminal tail of OxDC, there are four positively charged lysines, and two polar amino acids:

serine and cysteine (Cys383). There are numerous amino acids to choose from to selectively replace cysteine or serine with side chains more or less polar. However, Cys383 which is the only cysteine residue residing in OxDC was selected. The three amino acids selected to replace cysteine were:

arginine (R), serine (S) and alanine (A). The C383R, C383S and C383A mutants were created by standard site-directed mutagenesis and sequences of each gene was confirmed by DNA sequencing. The C383R, C383S and C383A mutants were expressed as described in Example 1 in 0.4 L scale shake flasks. *E. coli* cells were collected by centrifugation and lysed by a standard protocol:

*E. coli* cells were suspended in lysozyme solution and two cycles of freeze/thawing. Complete lysis of *E. coli* cells was confirmed microscope analysis. Soluble and insoluble parts of these mutant enzymes were separated by centrifugation. Mutant enzymes in the insoluble pellets were extracted according to the method described in Example 1. The quantity of total mutant enzymes in the soluble part and the insoluble part (the extracted enzymes) were determined by activity assay and protein concentration. The purity of the extracted mutant enzymes was estimated from SDS-PAGE. The results of the 3 mutants and wild type enzyme are shown in Table 1.

**[0115]** The expression levels of wild type OxDC (C383C), C383R, C383S, and C383A mutants of OxDC and their distributions in the lysate (soluble form) and cell debris pellet (insoluble forms, but extracted) are shown below. The data were obtained from 6 grams of *E. coli* cell paste, which is equal to approximately 4 grams of lysed cell pellet, or 0.4 L of culture.

TABLE 1. The expression levels of wild type OxDC (C383), C383R, C383S, and C383A mutants of OxDC and their distributions in the lysate (soluble form) and cell debris pellet (insoluble form, but extracted).

	OxDC in lysate (mg)	OxDC in pellet (mg)	Ratio of Soluble vs Insoluble	Total OxDC (mg)	Specific activity (U/mg)	Relative specific activity
C383R	12	62	0.19	74	72	1.06
C383 (Wild type)	6.3	108	0.05	114	68	1
C383S	3.2	510	0.006	513	61	0.90
C383A	0	530	0	530	28	0.41

**[0116]** As shown in Table 1, mutating C383 altered the distribution of OxDC between soluble and insoluble fractions with the more polar side chain generating mutants with a higher ratio of soluble proteins in the lysate. The higher ratios of soluble proteins in the lysate correlated with lower expression level, but higher specific activity. The C383R mutant showed 6% higher specific activity than the wild type, but expression level was much lower. Although the C383A mutant OxDC showed a slightly higher expression than level than the C383S mutant, the specific activity was less than half of the C383S mutant. The C383S mutant expression level was approximately 5 times higher than the expression level of wild type OxDC and its specific activity was 90% as compared to wild type. The other properties of the C383S mutant enzyme were further characterized and compared with the wild type. Both the wild type and C383S mutant of OxDC are active between pH 3.5 and 5.5 with optimum activity at pH 4.0. Both enzymes are stable between pH 3.5 and 9.5 and at temperatures approaching 60 °C for at least 1 hr. In addition, the wild type showed at least two major peaks on a phenyl-sepharose column indicating more than one OxDC isoform, while the C383S mutant showed only one peak on the same column and under identical conditions (Fig. 1). The two isoforms of wild type OxDC introduces a more obstacles in terms of purification due to separation of two similar isoforms. For example, it may require a gradient elution on hydrophobic interaction chromatography column to separate the two isoforms. The two isoforms may also decrease the final yield of purified enzyme because more purification steps are required and each additional purification step results in losses in yield. In addition, one of the two isoforms may be useless.

### Example 3

#### Alternative expression system for the C383S mutant

**[0117]** Construction of expression vectors. IPTG induction was compared with two other induction methods: rhamnose and temperature using a Lybradyn proprietary vector incorporated with the corresponding promoters. The results from small scale fermentation experiments indicated that all methods effectively expressed OxDC.

**[0118]** The vectors were constructed by standard molecular biological methods. The NdeI/BamHI fragment bearing the *E. coli* optimized *YvrK* gene was inserted into the NdeI/BamHI site of a Labradyn vector No.101 under the control of the rhamnose-inducible promoter to create the plasmid pOTrhamC383S, which was transformed into *E. coli* BW25113 for OxDC production. The temperature-inducible vector pOTIprC383S was generated by replacing the rhamnose-induced promoter from pOTrhamC383S with a temperature induced promoter  $\lambda_{PR}$  from phage lambda (lpr) carried by a Lybradyn vector No. 102 through MunI and AflII restriction sites. The expression vectors were later transformed into *E. coli* BW25113 for OxDC production. Other elements found in the vector include promoter and regulatory sequences, ribosome binding site, kanamycin/neomycin resistance, cer segregational stability element, and Rop plasmid copy number regulator sequences.

**[0119]** Comparison of expression level of the three expression vectors. Fermentation was performed in 200 mL flasks. The fermentation of OxDC by rhamnose induction was identical to IPTG induction as described in Example 1, except that 0.2% rhamnose was added at induction instead of 1.0 mM IPTG. The fermentation of OxDC by temperature induction was the same as IPTG and rhamnose induction except for two differences: *E. coli* was cultured at 30 °C instead of 37 °C and the induction was done by increasing the culture temperature to 42 °C.

**[0120]** *E. coli* cells were harvested and lysed and OxDC was extracted from cell debris according to the methods

described in Example 1. Both rhamnose and temperature induced expression systems yielded 400-600 mg of active C383S OxDC per liter of culture, a level close to IPTG expression (500 mg OxDC per liter of culture). Therefore, the temperature inducible expression system was selected.

## Example 4

### A simple purification process with solubility adjustment by pH

**[0121]** Background. OxDC has limited solubility at pH 4.5-7.8 for the wild type and pH 4.0-8.0 for the C383S mutant. OxDC solubility increases if the pH is greater than 8.5 for the wild type OxDC and pH 9.0 for the C383S mutant. Tris and arginine are selective binding ligands to OxDC; therefore, both can greatly increase OxDC solubility. The purification process is applicable for the wild type and C383S mutant; however, only the C383S mutant is used to illustrate the purification method.

**[0122]** Step 1: extraction of C383S from cell debris pellet. All purification steps were performed at room temperature. Before extraction of C383S, *E. coli* cells were lysed, cell debris was collected and washed with water to remove any soluble cell components according to the methods described in Example 1. However, the extraction of the OxDC from the cell debris here was different from Example 1. In Example 1, 0.75 M  $(\text{NH}_4)_2\text{SO}_4$  was added into 50 mM Tris buffer (pH 8.0) to extract OxDC from the pellet. In this method, extraction buffer was 50 mM Arginine or Tris HCl (pH 9.5) without addition of  $(\text{NH}_4)_2\text{SO}_4$ . The method was able to extract more of the C383S (> 90% of total C383S in the pellet) mutant enzyme than the method described in Example 1 (75% of the total C383S mutant that was expressed) with much less host cell DNA and other impurities. The purity of C383S was usually greater than 99% (Table 2). In addition, the concentration of the C383S mutant OxDC in the extract reached 120 g/L, which reduced water use and also reduced the scale of the following step (Step 2).

**[0123]** Step 2: filtration. The majority of the impurities found in the extract were endotoxin which can be removed by two to three depth filters after addition of 0.6 M NaCl: the first filter was rated at 3 micron, the second 1.2 micron and finally the third depth filter was 0.2 or 0.1 micron. After filtration, the extract contained reduced levels of endotoxin (Table 2) and was ready for precipitation. If higher purity was required, one hydrophobic interaction chromatography (HIC) column was introduced for further processing before precipitation.

**[0124]** Step 3 (optional): HIC column. The filtrated C383S mutant OxDC solution was loaded onto an HIC column pre-equilibrated with 0.6 M NaCl in 50 mM Arg or Tris, pH 9.5. OxDC flowed through the column while impurities bound to the column which removed the impurities from the C383S solution. The C383S mutant flow through was collected for precipitation.

**[0125]** Step 3: precipitation by pH adjustment. For pH adjustment, 0.2 M citrate buffer, pH 3.0 was added dropwise to the C383S solution while stirring until the pH reached 7.0. The C383S mutant solubility dropped to less than 1 g/L at pH 7.0; thus, 99% of C383S (if starting concentration of the C383S mutant was 100 g/L) precipitates and was collected by centrifugation. The collected C383S mutant pellet may be washed 2-3 times to remove remaining NaCl, arginine or Tris by 50 mM citrate buffer, pH 6.0. The washed C383S pellet was in a very pure form (Table 2).

Table 2. Summary of a typical purification process starting with 5 kg of lysed cell pellet. The data in this table is the analysis results for the OxDC materials obtained at the end of each step.

	Protein concentration (g/L)	Specific activity (U/mg protein)	Total amount protein (g)	Purity (SDS-PAGE )	DNA (ng/mg protein)	Endotoxin (EU/mg protein)
Extraction	99	45.4	440	100	3.4	22000
Filtration	90	44.0	420	100	4.0	4000
HIC	60	44.3	360	100	4.1	< 0.5
Precipitation	50-100	44.6	350	100	3.7	< 0.5

## Example 5

### Spray dry dose formulations (particle formation)

**[0126]** Process. All spray dry experiments were carried out with a Niro Mobile Minor. Typical spray dry operation conditions are as follows: inlet temperature: 180-220 °C, outlet temperature: 85-95 °C, flow rate of dry air: 60-90 kg/h,

atomization airflow: 8-15 kg/h, orifice diameter of the nozzle: 1-2 mm, feed flow rate: 1-4 kg/h. Table 3 summarizes compositions of different particle formulations according to this invention.

**[0127]** Results. Table 4 summarizes the specific activity of the C383S mutants in different spray dry particle formulations and in solution after redissolving the particles in phosphate buffer, pH 7.5. The polymer L 100-55 dissolved in water when pH is greater than 5.5. The control was the C383S mutant suspended in 50 mM citrate buffer without any protection from polymers, which lost 39% activity due to the high temperature and dehydration experienced during the spray dry process. The C383S mutant in formulations 1 and 2 was in solution and evenly distributed. The C383S mutant distribution in the outside layer of the spray dry microdrops might have inactivated during the spray dry process and thus resulted in 13% and 7% loss of activity, respectively. In contrast, the specific activity of the C383S mutant in formulations 3 to 8 were greater than formulation 1. When the structure of these particles is destroyed, for example, dissolving formulations 4-7 in 50 mM phosphate, pH 7.5, the specific activity returned to normal or even reduced levels as compared to free C383S, due to partial inactivation during spray drying.

**[0128]** Table 5 summarizes the stability data generated from these dry particles. Incubation at 45 °C for specified periods of time, showed excellent stability of formulations 1, 4 and 5.

**[0129]** Table 6 summarizes the results from in vitro pepsin protection testing. The particles were suspended in a pepsin (3.2 g/L)/acetate buffer, pH at 3.25, for 40 minutes at 37 °C while agitating at 1100 rpm. The remaining activity after treatment was measured by an activity assay. Formulation 1 did not give significant protection because it dissolved in water and destroyed the particle structure. Formulations 2 to 8 all showed protection from pepsin.

Table 3. Formulations that were tested by spray drying

	Formulation
1	0.6% OxDC, 6% trehalose, 1.2% PVA and 1.2% Eudragit L100 in 12 mM arginine, pH 8.5
2	2% OxDC, 2% trehalose, 2% arginine and 3.9% Eudragit L100-55, pH 9.0
3	3% OxDC, 2% trehalose, 2.6% arginine and 4.5% Eudragit L100-55, pH 5.4
4	The same as 2, except addition of 0.3% TEC
5	The same as 3 except without addition of arginine
6	3% OxDC, 2% trehalose, 2.6% arginine, 0.3% TEC and 4.5% Eudragit FS30D, pH 5.4
7	3% OxDC, 2% trehalose, 2.6% arginine, 0.3% TEC and 4.5% Eudragit RS, pH 5.4
8	3% OxDC, 2% trehalose, 2.6% arginine, 0.3% TEC and 2.25% Eudragit RL and 2.25% Eudragit RS, pH 5.4

Table 4. The specific activity of C383S in spray drying particles and in the solutions after these particles were destructured by dissolving in phosphate buffer at pH 7.5.

Test	C383S specific activity in particles (U/mg protein) <sup>B</sup>	C383S specific activity change (%)	C383S specific activity after particles dissolved (U/mg protein)
Free C383S	45	100	-
Control <sup>A</sup>	27.5	61	27.0
1	39.2	87	39.4
2	48.9	93	48.5
3	57.2	127	-
4	63.5	141	44.3
5	55.8	124	42.6
6	46.8	104	41.7
7	57.2	127	43.0

(continued)

Test	C383S specific activity in particles (U/mg protein) <sup>B</sup>	C383S specific activity change (%)	C383S specific activity after particles dissolved (U/mg protein)
8	57.2	127	-
<sup>A</sup> Control: C383S suspended in 50 mM citrate buffer, pH 6.0, and spray dried under the same conditions. <sup>B</sup> Calculation of C383S specific activity: B/A. Here, A = the amount of C383S (mg) in 1 gram of solid mass of the feed; B = the total activity (U) in one gram of dry particles obtained from spray dry.			

Table 5. The activity remaining after a certain period of incubation at 45 °C.

Test	0 week	1 week	2 week	4 week	8 week	12 week
Control						
1	36.1	-	37.6	40.0	-	41.6
2	42	35.9				
3	57.2	44.2				
4	63.5	52.2	-	65.3		
5	54.9	-	51.4	47.2		
6	46.8	29.1				
7	57.1	3.2				
8	57.1	42.5				

Table 6. The activity after 40 min treated with 3.2 mg/ml pepsin solution at pH 3.25.

Test	C383S activity remained (%)
Control	22
1	30
2	72
3	75
4	82
5	80
6	89
7	77
8	79

**Example 6****In vivo dose of oxalate reducing particles**

**[0130]** A 10-day study was conducted in male Sprague-Dawley rats. The purpose of this study was to evaluate the effects of administration of formulation 5 in Table 2 on the urinary response to oxalate loading in male Sprague-Dawley rats.

**[0131]** The study used 18 male Sprague-Dawley rats that were divided into 3 groups as shown in Table 7, which were administered oral doses of formulation 5 (Group 3) or vehicle (Group 2, control, 50 mM sodium citrate, pH 4.49) together with high oxalate diet. Group 1 was another control group, the 6 rats in this group were not administered a high oxalate diet, nor formulation 5. The rats were oral gavaged twice a day (BID). Rats in Group 3 received 500U of formulation 5. After the rats were dosed, 30 minutes after the start of feeding, the rats were given access to food for an additional 1.5

hours in the morning (7:00-9:00AM) and evening (3:30-5:30PM). Food was weighed before the morning feeding and after both the morning and afternoon feedings. The rats were fed in their normal cages and immediately transferred to metabolic cages after dose administration on days -1, 4 and 9 in order to capture urine and fecal excretions.

#### Oxalate determination

**[0132]** Quantitative oxalate determination from urine was determined by the colorimetric kit purchased from Trinity Biotech USA (St. Louis, MO). The assay is comprised of two enzymatic reactions as follows: (1) oxalate is oxidized to CO<sub>2</sub> and H<sub>2</sub>O<sub>2</sub> by oxalate oxidase and (2) H<sub>2</sub>O<sub>2</sub> reacts with 3-methyl-2-benzothiazolinone hydrazone (MBTH) and 3-(dimethylamino) benzoic acid (DMAB) in the presence of peroxidase to yield an indamine dye which can be detected at 590 nm. Urinary oxalate is calculated from a standard curve.

#### Creatinine determination

**[0133]** Creatinine determination by LiquiColor® Procedure No. 0420. The creatinine colorimetric kit for the quantitative determination of creatinine in urine was purchased from StanBio Laboratory (Bocrne, Texas). The assay is based on a modification of the automated reaction rate of Fabinay and Eringshausen method in which creatinine reacts with picric acid in alkaline conditions to form a color complex at 510 nm. The color development is directly proportional to the creatinine concentration. Urinary creatinine is calculated from a standard curve.

Table 7 Study Design

Group	Diet	Dose	# of Rats	Days of dosing	Urinary oxalate excretion (Ox/Cr)
1	No Ox	50 mM Citrate	6	10	
2	HOD	50 mM Citrate	6	10	
3	HOD	Formulation 5	6	10	
HOD = High Oxalate Diet (Harlan Teklad TD04493) No Ox= Harlan Teklad TD89222 Groups 1 and 2: 50 mM sodium citrate, pH 4.49 Group 3: formulation 5					

#### Results

**[0134]** Dosing formulation 5 with high oxalate diet significantly decreased urinary oxalate excretion of all six rats in group 3. On an average 500U of formulation 5 fed with dietary oxalate was found to reduce urinary oxalate excretion by 49-59% (Fig. 2).

#### SEQUENCE LISTING

##### [0135]

<110> Oxthera Intellectual Property AB Li, Qingshan Cowley, Aaron B Gölander, Carl-Gustaf Sidhu, Harmmeet

<120> PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES

<130> P14151 PC / P13530

<160> 19

<170> PatentIn version 3.5

<210> 1

<211> 1152

<212> DNA

<213> Bacillus subtilis

# EP 2 449 098 B1

<400> 1

	aaaaaacaaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
5	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa ccttgcattc	240
10	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tggctacttc cgtcaggcct gccgcactcc	420
15	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
20	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
25	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
30	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
35	aaatgcagta aa	1152

<210> 2

<211> 1164

<212> DNA

40 <213> Artificial sequence

<220>

<223> recombined sequence, originally from Bacillus subtilis

45 <400> 2

50

55



EP 2 449 098 B1

	catatgaaaa aacagaatga cattccacag ccgattcgcg gcgataaagg cgcgaccgtc	60
	aaaattcctc gcaatatcga acgcgaccgc cagaatccgg atatgctggt gccgccggag	120
5	acggaccatg gcacggtgtc taacatgaaa ttctctttta gcgataccca caaccgcctg	180
	gaaaaagggtg gctacgcgcg cgagggttacc gtccgtgaac tgccaattag cgaaaatctg	240
	gcttcggtta acatgcgtct gaaaccaggt gctatccgtg agctgcactg gcacaaggaa	300
10	gcggaatggg cgtatatgat ttacgggttca gcacgtgtta ccatcgtaga cgagaaagggt	360
	cgtagcttta tcgatgatgt tggcgaagggt gatctgtggt atttcccatc tggcctgccg	420
	cattcgattc aggcgctgga agaaggcgcgt gaatttctgc tgggtgttcga tgatggttcc	480
15	ttttctgaaa acagcacgtt ccagctgacg gattggctgg cgcacacgcc gaaagaagtc	540
	attgcggcca attttgggggt aaccaaagaa gaaatttcca acctgccggg caaagaaaag	600
	tatatTTTTg agaatcagct gccgggctct ctgaaggacg atattgtaga aggccctaac	660
20	ggtgagggtc cgtatccgtt cacctatcgt ctgctggagc aggaaccgat tgaaagcgaa	720
	ggcggtaaag tttatatcgc agattccact aactttaag tctccaagac cattgccagc	780
	gccctgggtca ccgtggaacc gggagcgatg cgcgagctgc actggcatcc gaacacgcac	840
25	gaatggcagt attatatTtc cggcaaagca cgcagtaccg tttttgcctc agatggacac	900
	gctcgcacgt ttaattatca agcgggtgat gttggctacg ttcctttcgc catgggccat	960
	tatgtagaaa atatcggcga tgaaccactg gtgtttctgg agatctttaa agatgaccac	1020
30	tatgccgatg tttcactgaa tcagtggctg gccatgctgc cggaaacttt tgttcaggcg	1080
	catctggacc tgggtaaaga ctttacggat gtgctgagca aagaaaaaca cccggtagtc	1140
	aagaagaaat gcagtaaagg atcc	1164
35	<210> 3	
	<211> 1152	
	<212> DNA	
	<213> Artificial Sequence	
40	<220>	
	<223> recombined sequence, originally from Bacillus subtilis	
	<400> 3	
45	aaaaaacaaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
50	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa cttgcatcc	240
	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
55	tgggcttata tgatttacgg aagtgcaaga gtcacaattg tagatgaaaa agggcgcagc	360

# EP 2 449 098 B1

	tttattgacg atgtaggtga aggagacctt tggctacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
5	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagttaaata gatgatattg tggaagggcc gaatggcgaa	660
10	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
15	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
20	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa cttttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccacgt agtgaaaaag	1140
	aaatctagta aa	1152
25	<210> 4 <211> 1152 <212> DNA <213> Artificial sequence	
30	<220> <223> recombined sequence, originally from Bacillus subtilis	
	<400> 4	
35		
40		
45		
50		
55		

# EP 2 449 098 B1

	aaaaa caaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa cttgcatcc	240
	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tgggtacttc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgagggagga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
25	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900

-----

	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
30	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttggttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccaggt agtgaaaaag	1140
35	aaatccagta aa	1152

<210> 5

<211> 1152

<212> DNA

40 <213> Artificial sequence

<220>

<223> recombined sequence, originally from Bacillus subtilis

45 <400> 5

50

55

# EP 2 449 098 B1

	aaaaa caaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatattg cccgggaagt gacagtacgt gaattgccga tttcagaaaa cttgcatcc	240
	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgatttacgg aagtgcgaaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggtga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttatc catttactta ccgccttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
25	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
30	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
	aaatcaagta aa	1152

35 <210> 6  
 <211> 1152  
 <212> DNA  
 <213> Artificial Sequence

40 <220>  
 <223> recombined sequence, originally from Bacillus subtilis

<400> 6

45

50

55

EP 2 449 098 B1

	aaaaaaca	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat	120
5	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa	180
	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcaccc	240
	gtaaatatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa	300
10	tgggcttata	tgattttacg	aagtgcgaaga	gtcacaattg	tagatgaaaa	agggcgcagc	360
	tttattgacg	atgtaggtga	aggagacctt	tggtacttcc	cgtcaggcct	gccgcactcc	420
	atccaagcgc	tggaggaggg	agctgagttc	ctgctcgtgt	ttgacgatgg	atcattctct	480
15	gaaaacagca	cgttccagct	gacagattgg	ctggcccaca	ctccaaaaga	agtcattgct	540
	gcgaacttcg	gcgtgacaaa	agaagagatt	tccaatttgc	ctggcaaaga	aaaatatata	600
	tttgaaaacc	aacttcctgg	cagtttaaaa	gatgatattg	tggaagggcc	gaatggcgaa	660
20	gtgccttata	cattttactta	ccgccttctt	gaacaagagc	cgatcgaatc	tgaggaggga	720
	aaagtataca	ttgcagattc	gacaaacttc	aaagtgtcta	aaaccatcgc	atcagcgcct	780
	gtaacagtag	aacccggcgc	catgagagaa	ctgcactggc	acccgaatac	ccacgaatgg	840
25	caatactaca	tctccggtaa	agctagaatg	accgtttttg	catctgacgg	ccatgccaga	900
	acgtttaatt	accaagccgg	tgatgtcggg	tatgtaccat	ttgcaatggg	tcattacggt	960
	gaaaacatcg	gggatgaacc	gcttgtcttt	ttagaaatct	tcaaagacga	ccattatgct	1020
30	gatgtatctt	taaaccaatg	gcttgccatg	cttcctgaaa	catttgttca	agcgcacctt	1080
	gacttgggca	aagactttac	tgatgtgctt	tcaaaagaaa	agcaccagct	agtgaaaaag	1140
	aaatcgagta	aa					1152

35 <210> 7  
 <211> 1152  
 <212> DNA  
 <213> Artificial sequence

40 <220>  
 <223> recombined sequence, originally from Bacillus subtilis  
 <400> 7

45	aaaaaaca	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat	120
	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa	180
50	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcaccc	240
	gtaaatatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa	300
	tgggcttata	tgattttacg	aagtgcgaaga	gtcacaattg	tagatgaaaa	agggcgcagc	360
55	tttattgacg	atgtaggtga	aggagacctt	tggtacttcc	cgtcaggcct	gccgcactcc	420
	atccaagcgc	tggaggaggg	agctgagttc	ctgctcgtgt	ttgacgatgg	atcattctct	480

-----

# EP 2 449 098 B1

	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
5	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
	gtgcccttatc catttactta ccgccttctt gaacaagagc cgatcgaatc tgagggagga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
10	gtaacagtag aaccggcg gc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
15	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa ctttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
20	aaaagtagta aa	1152

<210> 8

<211> 1152

<212> DNA

25 <213> Artificial Sequence

<220>

<223> recombined sequence, originally from Bacillus subtilis

30 <400> 8

35

40

45

50

55

# EP 2 449 098 B1

	aaaaaaca	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat	120
5	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa	180
	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcaccc	240
	gtaaaatatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa	300
10	tgggcttata	tgatttacgg	aagtgcgaaga	gtcacaattg	tagatgaaaa	agggcgcagc	360
	tttattgacg	atgtaggtga	aggagacctt	tggtacttcc	cgtcaggcct	gccgcactcc	420
	atccaagcgc	tggaggaggg	agctgagttc	ctgctcgtgt	ttgacgatgg	atcattctct	480
15	gaaaacagca	cgttccagct	gacagattgg	ctggcccaca	ctccaaaaga	agtcattgct	540
	gcgaacttcg	gcgtgacaaa	agaagagatt	tccaatttgc	ctggcaaaga	aaaatatata	600
	tttgaaaacc	aacttcctgg	cagtttaaaa	gatgatattg	tggaagggcc	gaatggcgaa	660
20	gtgccttata	catttactta	ccgccttctt	gaacaagagc	cgatcgaatc	tgagggagga	720
	aaagtataca	ttgcagattc	gacaaacttc	aaagtgtcta	aaaccatcgc	atcagcgctc	780
	gtaacagtag	aaccggcg	catgagagaa	ctgcactggc	acccgaatac	ccacgaatgg	840
25	caatactaca	tctccggtaa	agctagaatg	accgtttttg	catctgacgg	ccatgccaga	900
	acgtttaatt	accaagccgg	tgatgtcgga	tatgtaccat	ttgcaatggg	tcattacggt	960
	gaaaacatcg	gggatgaacc	gcttgtcttt	ttagaaatct	tcaaagacga	ccattatgct	1020
30							
	gatgtatctt	taaaccaatg	gcttgccatg	cttcctgaaa	catttgttca	agcgcacctt	1080
	gacttgggca	aagactttac	tgatgtgctt	tcaaaagaaa	agcaccaggt	agtgaaaaag	1140
35	aaaagcagta	aa					1152

<210> 9

<211> 1152

<212> DNA

40 <213> Artificial Sequence

<220>

<223> recombined sequence, originally from Bacillus subtilis

45 <400> 9

50

55

EP 2 449 098 B1

	aaaaa caaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa ccttgcattcc	240
	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
25	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacggt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
30	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa cttttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
	aaacgtagta aa	1152

35 <210> 10  
 <211> 1152  
 <212> DNA  
 <213> Artificial sequence

40 <220>  
 <223> recombined sequence, originally from Bacillus subtilis

<400> 10

45	aaaaa caaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
----	---	----

50

55



# EP 2 449 098 B1

	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
5	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa ccttgcattcc	240
	gtaaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
	tgggcttata tgattttacgg aagtgaaga gtcacaattg tagatgaaaa agggcgcagc	360
10	tttattgacg atgtaggtga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
15	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgagggagga	720
20	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aaccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
25	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacggt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttggtca agcgcacctt	1080
30	gacttgggca aagactttac tgatgtgctt tcaaaaagaaa agcaccacgt agtgaaaaag	1140
	aaacgcagta aa	1152

35  
 <210> 11  
 <211> 1152  
 <212> DNA  
 <213> Artificial Sequence

40  
 <220>  
 <223> recombined sequence, originally from Bacillus subtilis

<400> 11

45

50

55

# EP 2 449 098 B1

	aaaaa	caaaa	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat		120
5	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa		180
	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcattcc		240
	gtaaataatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa		300
10	tgggcttata	tgatttacgg	aagtgcaaga	gtcacaattg	tagatgaaaa	agggcgcagc		360
	tttattgacg	atgtaggatga	aggagacctt	tggtacttcc	cgtcaggcct	gccgcactcc		420
	atccaagcgc	tggaggaggg	agctgagttc	ctgctcgtgt	ttgacgatgg	atcattctct		480
15	gaaaacagca	cgttccagct	gacagattgg	ctggcccaca	ctccaaaaga	agtcattgct		540
	gcgaacttcg	gcgtgacaaa	agaagagatt	tccaatttgc	ctggcaaaga	aaaatatata		600
20	tttgaaaacc	aacttcctgg	cagtttaaaa	gatgatattg	tggaagggcc	gaatggcgaa		660
	gtgccttatc	catttactta	ccgccttctt	gaacaagagc	cgatcgaatc	tgaggaggga		720
	aaagtataca	ttgcagattc	gacaaacttc	aaagtgtcta	aaaccatcgc	atcagcgctc		780
25	gtaacagtag	aaccggcg	catgagagaa	ctgcactggc	acccgaatac	ccacgaatgg		840
	caatactaca	tctccggtaa	agctagaatg	accgtttttg	catctgacgg	ccatgccaga		900
	acgtttaatt	accaagccgg	tgatgtcgga	tatgtaccat	ttgcaatggg	tcattacgtt		960
30	gaaaacatcg	gggatgaacc	gcttgtcttt	ttagaaatct	tcaaagacga	ccattatgct		1020
	gatgtatctt	taaaccaatg	gcttgccatg	cttcctgaaa	catttggttca	agcgcacctt		1080
	gacttgggca	aagactttac	tgatgtgctt	tcaaaaagaaa	agcaccagct	agtgaaaaag		1140
35	aaacgaagta	aa						1152

<210> 12

<211> 1152

40 <212> DNA

<213> Artificial Sequence

<220>

<223> recombined sequence, originally from Bacillus subtilis

45

<400> 12

50

55

# EP 2 449 098 B1

	aaaaa caaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatattg cccgggaagt gacagtacgt gaattgccga tttcagaaaa cttgcatcc	240
	gtaaataatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgagggagga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgtc	780
	gtaacagtag aaccggcgc catgagagaa ctgactggc acccgaatac ccacgaatgg	840
25	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
30	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttggtca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaaagaaa agcaccagc agtgaaaaag	1140

35	aaacggagta aa	1152
----	---------------	------

	<210> 13
	<211> 1152
40	<212> DNA
	<213> Artificial sequence

	<220>
	<223> recombined sequence, originally from Bacillus subtilis
45	<400> 13

50

55

EP 2 449 098 B1

	aaaaaacaaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa ccttgcattc	240
	gtaaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttatc catttactta ccgccttctt gaacaagagc cgatcgaatc tgagggagga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
25	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
30	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa cttttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
	aaaagaagta aa	1152
35	<210> 14 <211> 1152 <212> DNA <213> Artificial Sequence	
40	<220> <223> recombined sequence, originally from Bacillus subtilis  <400> 14	
45	aaaaaacaaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
50	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180

# EP 2 449 098 B1

	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa ccttgcattcc	240
	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
5	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tggtagcttc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
10	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
15	gtgccttatc catttactta ccgcttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aaccggcgc catgagagaa ctgactggc acccgaatac ccacgaatgg	840
20	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccattgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
25	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttggtca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
	aaaaggagta aa	1152

30 <210> 15  
 <211> 1152  
 <212> DNA  
 <213> Artificial sequence

35 <220>  
 <223> recombined sequence, originally from Bacillus subtilis

<400> 15

40

45

50

55

# EP 2 449 098 B1

	aaaaa	caaaa	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat		120
5	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa		180
	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcaccc		240
	gtaaatatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa		300
10	tgggcttata	tgatttacgg	aagtgcaga	gtcacaattg	tagatgaaaa	agggcgcagc		360
	tttattgacg	atgtaggtga	aggagacctt	tggtacttcc	cgtcaggcct	gccgcactcc		420
	atccaagcgc	tggaggaggg	agctgagttc	ctgctcgtgt	ttgacgatgg	atcattctct		480
15	gaaaacagca	cgttccagct	gacagattgg	ctggcccaca	ctccaaaaga	agtcattgct		540
	gcgaacttcg	gcgtgacaaa	agaagagatt	tccaatttgc	ctggcaaaga	aaaatatata		600
	tttgaaaacc	aacttcctgg	cagtttaaaa	gatgatattg	tggaagggcc	gaatggcgaa		660
20	gtgccttatc	catttactta	ccgccttctt	gaacaagagc	cgatcgaatc	tgaggggagga		720
	aaagtataca	ttgcagattc	gacaaacttc	aaagtgtcta	aaaccatcgc	atcagcgctc		780
25	gtaacagtag	aacccggcgc	catgagagaa	ctgcactggc	acccgaatac	ccacgaatgg		840
	caatactaca	tctccggtaa	agctagaatg	accgtttttg	catctgacgg	ccatgccaga		900
	acgtttaatt	accaagccgg	tgatgtcggg	tatgtaccat	ttgcaatggg	tcattacggt		960
30	gaaaacatcg	gggatgaacc	gcttgtcttt	ttagaaatct	tcaaagacga	ccattatgct		1020
	gatgtatctt	taaaccaatg	gcttgccatg	cttcctgaaa	catttggttca	agcgcacctt		1080
	gacttgggca	aagactttac	tgatgtgctt	tcaaaagaaa	agcaccagct	agtgaaaaag		1140
35	aaagctagta	aa						1152
	<210> 16							
	<211> 1152							
	<212> DNA							
40	<213> Artificial Sequence							
	<220>							
	<223> recombined sequence, originally from Bacillus subtilis							
45	<400> 16							
50								
55								

EP 2 449 098 B1

	aaaaaacaaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa ccttgcatcc	240
	gtaaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgattttacgg aagtgcgaaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggtga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttata catttactta ccgccttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
25	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacgtt	960
	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
30	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttggtca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
	aaagccagta aa	1152
35	<210> 17 <211> 1152 <212> DNA <213> Artificial Sequence	
40	<220> <223> recombined sequence, originally from Bacillus subtilis	
	<400> 17	
45		
50		
55		

EP 2 449 098 B1

	aaaaaaca	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat	120
5	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa	180
	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcattcc	240
	gtaaatatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa	300
10	tgggcttata	tgattttacg	aagtgcgaag	gtcacaattg	tagatgaaaa	agggcgagc	360
	tttattgacg	atgtagggtg	aggagacctt	tgggtacttc	cgtaggcct	gccgcactcc	420
	atccaagcgc	tggaggaggg	agctgagttc	ctgctcgtgt	ttgacgatgg	atcattctct	480
15	gaaaacagca	cggtccagct	gacagattgg	ctggcccaca	ctccaaaaga	agtcattgct	540
	gcgaacttcg	gcgtgacaaa	agaagagatt	tccaatttgc	ctggcaaaga	aaaatatata	600
	tttgaaaacc	aacttcctgg	cagtttaaaa	gatgatattg	tgggaaggcc	gaatggcgaa	660
20	gtgccttata	catttactta	ccgccttctt	gaacaagagc	cgatcgaatc	tgaggaggga	720
	aaagtataca	ttgcagattc	gacaaacttc	aaagtgtcta	aaaccatcgc	atcagcgctc	780
	gtaacagtag	aacccggcgc	catgagagaa	ctgcactggc	acccgaatac	ccacgaatgg	840
25	caatactaca	tctccggtaa	agctagaatg	accgtttttg	catctgacgg	ccatgccaga	900
	acgtttaatt	accaagccgg	tgatgtcggg	tatgtaccat	ttgcaatggg	tcattacggt	960
	gaaaacatcg	gggatgaacc	gcttgtcttt	ttagaaatct	tcaaagacga	ccattatgct	1020
30	gatgtatctt	taaaccaatg	gcttgccatg	cttcctgaaa	catttgttca	agcgcacctt	1080
	gacttgggca	aagactttac	tgatgtgctt	tcaaaagaaa	agcaccagct	agtgaaaaag	1140
	aaagcaagta	aa					1152
35	<210> 18 <211> 1152 <212> DNA <213> Artificial Sequence						
40	<220> <223> recombined sequence, originally from Bacillus subtilis						
	<400> 18						
45	aaaaaaca	atgacattcc	gcagccaatt	agaggagaca	aaggagcaac	ggtaaaaatc	60
	ccgcgcaata	ttgaaagaga	ccggcaaaac	cctgatatgc	tcgttccgcc	tgaaaccgat	120
	catggcaccg	tcagcaatat	gaagttttca	ttctctgata	ctcataaccg	attagaaaaa	180
50	ggcggatatg	cccgggaagt	gacagtacgt	gaattgccga	tttcagaaaa	ccttgcattcc	240
	gtaaatatgc	ggctgaagcc	aggcgcgatt	cgcgagcttc	actggcataa	agaagctgaa	300
55							



# EP 2 449 098 B1

	tgggcttata tgattttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggtga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
5	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
10	tttgaaaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
	gtgccttatc catttactta ccgccttctt gaacaagagc cgatcgaatc tgagggagga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
15	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtacatc ttgcaatggg tcattacgtt	960
20	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa cttttgttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccagc agtgaaaaag	1140
25	aaagcgagta aa	1152

<210> 19

<211> 1152

<212> DNA

30 <213> Artificial sequence

<220>

<223> recombined sequence, originally from Bacillus subtilis

35 <400> 19

40

45

50

55

EP 2 449 098 B1

	aaaaaacaaa atgacattcc gcagccaatt agaggagaca aaggagcaac ggtaaaaatc	60
	ccgcgcaata ttgaaagaga ccggcaaaac cctgatatgc tcgttccgcc tgaaaccgat	120
5	catggcaccg tcagcaatat gaagttttca ttctctgata ctcataaccg attagaaaaa	180
	ggcggatatg cccgggaagt gacagtacgt gaattgccga tttcagaaaa cttgcatcc	240
	gtaaatatgc ggctgaagcc aggcgcgatt cgcgagcttc actggcataa agaagctgaa	300
10	tgggcttata tgatttacgg aagtgcaga gtcacaattg tagatgaaaa agggcgcagc	360
	tttattgacg atgtaggatga aggagacctt tgggtacttcc cgtcaggcct gccgcactcc	420
	atccaagcgc tggaggaggg agctgagttc ctgctcgtgt ttgacgatgg atcattctct	480
15	gaaaacagca cgttccagct gacagattgg ctggcccaca ctccaaaaga agtcattgct	540
	gcgaacttcg gcgtgacaaa agaagagatt tccaatttgc ctggcaaaga aaaatatata	600
	tttgaacc aacttcctgg cagtttaaaa gatgatattg tggaagggcc gaatggcgaa	660
20	gtgccttatc catttactta ccgccttctt gaacaagagc cgatcgaatc tgaggaggga	720
	aaagtataca ttgcagattc gacaaacttc aaagtgtcta aaaccatcgc atcagcgctc	780
	gtaacagtag aacccggcgc catgagagaa ctgcactggc acccgaatac ccacgaatgg	840
25		
30		
35		
40		
45		
50		
55		

EP 2 449 098 B1

	caatactaca tctccggtaa agctagaatg accgtttttg catctgacgg ccatgccaga	900
	acgtttaatt accaagccgg tgatgtcggg tatgtaccat ttgcaatggg tcattacggt	960
5	gaaaacatcg gggatgaacc gcttgtcttt ttagaaatct tcaaagacga ccattatgct	1020
	gatgtatctt taaaccaatg gcttgccatg cttcctgaaa catttggttca agcgcacctt	1080
	gacttgggca aagactttac tgatgtgctt tcaaaagaaa agcaccacgt agtgaaaaag	1140
10	aaaggaagta aa	1152

15

20

25

30

35

40

45

50

55

## Claims

1. Spray-dried particles comprising one or more recombinant proteins selected from the group consisting of the C383S and the C383A mutant of the oxalate decarboxylase (OxDC) wild type recombinant protein according to SEQ. ID NO. 1 or SEQ. ID NO. 2, or a protein encoded by a sequence selected from SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18, or SEQ. ID NO. 19; and a polymeric material, wherein said proteins are prepared as nano- or micro-agglomerates.
2. Spray-dried particles according to claim 1, wherein the oxalate reducing enzyme is the C383S mutant of the OxDC wild type recombinant protein or a protein encoded by a sequence selected from SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7 or SEQ. ID NO. 8.
3. Spray-dried particles according to claim 1, wherein the oxalate reducing enzyme is the C383A mutant of the OxDC wild type recombinant protein or a protein encoded by a sequence selected from SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18 or SEQ. ID NO. 19.
4. Spray-dried particles according to any one of claims 1-3, wherein the activity of the one or more oxalate reducing enzymes when present in said particles at the most decreases to about 30% when incubated in a 3.2 mg/ml pepsin solution having a pH of about 3.2 for 40 minutes with the initial activity being set to 100%.
5. Spray-dried particles according to any one of claims 1-4, wherein the polymeric material is a poly(meth)acrylate.
6. A composition comprising spray-dried particles as defined in any one of claims 1-5.
7. The composition of claim 6, wherein the composition is an oral dosage form.
8. The composition of claim 6 or 7 in the form of a sachet, tablet, capsule, chewable tablet, quick dissolve tablet, oral disintegrating tablet, liquids, syrups, or elixirs or other delivery format.
9. The composition of any one of claims 6-8 for use in a method of treatment of a human or animal subject by reducing oxalate present in the stomach thereby reducing the absorption of said oxalate, said method comprising orally administering the composition to the stomach of the human or animal subject.
10. The composition for use according to claim 9, wherein reducing absorption of oxalate provides treatment for an oxalate-related condition selected from the group consisting of hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease, urolithiasis, vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, post-gastrointestinal surgery conditions, and post-bariatric surgery conditions, post-surgery for obesity conditions, or post-antibiotic treatment.

## Patentansprüche

1. Sprühgetrocknete Teilchen, die Folgendes umfassen: ein oder mehrere rekombinante Proteine, die aus der aus Folgendem bestehenden Gruppe ausgewählt sind: dem C383S- und dem C383A-Mutant des rekombinanten Oxalat-Decarboxylase-(OxDC-)Wildtyp-Proteins gemäß SEQ ID Nr. 1 oder SEQ ID Nr. 2 oder einem durch eine aus SEQ ID Nr. 3, SEQ ID Nr. 4, SEQ ID Nr. 5, SEQ ID Nr. 6, SEQ ID Nr. 7, SEQ ID Nr. 8, SEQ ID Nr. 15, SEQ ID Nr. 16, SEQ ID Nr. 17, SEQ ID Nr. 18 oder SEQ ID Nr. 19 ausgewählte Sequenz kodierten Protein; und ein Polymermaterial, wobei die Proteine als Nano- oder Mikroagglomerate hergestellt sind.
2. Sprühgetrocknete Teilchen nach Anspruch 1, wobei das oxalatreduzierende Enzym der C383S-Mutant des rekombinanten OxDC-Wildtyp-Proteins oder ein durch eine aus SEQ ID Nr. 3, SEQ ID Nr. 4, SEQ ID Nr. 5, SEQ ID Nr. 6, SEQ ID Nr. 7 oder SEQ ID Nr. 8 ausgewählte Sequenz kodiertes Protein ist.
3. Sprühgetrocknete Teilchen nach Anspruch 1, wobei das oxalatreduzierende Enzym der C383A-Mutant des rekombinanten OxDC-Wildtyp-Proteins oder ein durch eine aus SEQ ID Nr. 15, SEQ ID Nr. 16, SEQ ID Nr. 17, SEQ ID Nr. 18 oder SEQ ID Nr. 19 ausgewählte Sequenz kodiertes Protein ist.

4. Sprühgetrocknete Teilchen nach einem der Ansprüche 1 - 3, wobei die Aktivität der einen oder mehreren oxalatreduzierenden Enzyme, wenn in den Teilchen vorhanden, bei einer Inkubation in einer 3,2 mg/ml-Pepsinlösung, die einen pH-Wert von etwa 3,2 aufweist, für 40 Minuten höchstens auf etwa 30 % abnimmt, wobei die Anfangsaktivität auf 100 % eingestellt ist.
5. Sprühgetrocknete Teilchen nach einem der Ansprüche 1 - 4, wobei das Polimermaterial ein Poly(meth)acrylat ist.
6. Zusammensetzung, die sprühgetrocknete Teilchen nach einem der Ansprüche 1 - 5 umfasst.
7. Zusammensetzung nach Anspruch 6, wobei die Zusammensetzung in oraler Dosierungsform vorliegt.
8. Zusammensetzung nach Anspruch 6 oder 7 in Form eines Beutels, einer Tablette, Kapsel, Kautablette, schnell auflösenden Tablette, oral zerfallenden Tablette, von Flüssigkeiten, Sirupen oder Elixieren oder in einem anderen Abgabeformat.
9. Zusammensetzung nach einem der Ansprüche 6 - 8 zur Verwendung bei einem Verfahren zur Behandlung eines menschlichen oder tierischen Individuums zur Reduzierung von in dem Magen vorhandenen Oxalat, wodurch die Absorption des Oxalats reduziert wird, wobei das Verfahren die orale Verabreichung der Zusammensetzung an den Magen des menschlichen oder tierischen Individuums umfasst.
10. Zusammensetzung zur Verwendung nach Anspruch 9, wobei die Reduzierung der Oxalat-Absorption eine Behandlung einer oxalatbezogenen Erkrankung bereitstellt, die aus der aus Folgendem bestehenden Gruppe ausgewählt ist: Hyperoxalurie, absorbtive Hyperoxalurie, enterische Hyperoxalurie, primäre Hyperoxalurie, idiopathische Kalziumoxalatnierensteinerkrankung, Urolithiasis, Vulvodynie, mit terminaler Nierenkrankheit in Verbindung stehende Oxalose, Erregungsleiterstörungen, entzündliche Darmerkrankung, Crohn-Krankheit, Colitis ulcerosa, Zustände nach gastrointestinaler Operation und Zustände nach baritratischer Operation, Zustände nach Operationen bezogen auf Fettleibigkeit oder Antibiotika-Folgebehandlung.

## Revendications

1. Particules séchées par atomisation comprenant une ou plusieurs protéines recombinantes sélectionnées dans le groupe constitué du mutant C383S et C383A de la protéine recombinante de type sauvage de l'oxalate décarboxylase (OxDC) selon SEQ. ID NO. 1 ou SEQ. ID NO. 2, ou d'une protéine codée par une séquence sélectionnée parmi SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7, SEQ. ID NO. 8, SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18 ou SEQ. ID NO. 19 ; et un matériau polymère, dans lesquelles lesdites protéines sont préparées sous la forme de nano- ou de micro-agglomérats.
2. Particules séchées par atomisation selon la revendication 1, dans lesquelles l'enzyme de réduction d'oxalate est le mutant C383S de la protéine recombinante de type sauvage de l'OxDC ou une protéine codée par une séquence sélectionnée parmi SEQ. ID NO. 3, SEQ. ID NO. 4, SEQ. ID NO. 5, SEQ. ID NO. 6, SEQ. ID NO. 7 ou SEQ. ID NO. 8.
3. Particules séchées par atomisation selon la revendication 1, dans lesquelles l'enzyme de réduction d'oxalate est le mutant C383A de la protéine recombinante de type sauvage de l'OxDC ou une protéine codée par une séquence sélectionnée parmi SEQ. ID NO. 15, SEQ. ID NO. 16, SEQ. ID NO. 17, SEQ. ID NO. 18 ou SEQ. ID NO. 19.
4. Particules séchées par atomisation selon l'une quelconque des revendications 1 à 3, dans lesquelles l'activité des une ou plusieurs enzymes de réduction d'oxalate, quand elles sont présentes dans lesdites particules, diminue au plus à environ 30 % quand elles sont mises en incubation dans 3,2 mg/ml d'une solution de pepsine ayant un pH d'environ 3,2 pendant 40 minutes, l'activité initiale étant fixée à 100 %.
5. Particules séchées par atomisation selon l'une quelconque des revendications 1 à 4, dans lesquelles le matériau polymère est un poly(méth)acrylate.
6. Composition comprenant les particules séchées par atomisation selon l'une quelconque des revendications 1 à 5.
7. Composition selon la revendication 6, dans laquelle la composition est une forme galénique orale.

8. Composition selon la revendication 6 ou 7, sous la forme d'un sachet, d'un comprimé, d'une capsule, d'un comprimé à mâcher, d'un comprimé à dissolution rapide, d'un comprimé à délitement oral, de liquides, de sirops ou d'élixirs ou d'un autre format d'administration.

5 9. Composition selon l'une quelconque des revendications 6 à 8, pour son utilisation dans un procédé de traitement d'un sujet humain ou animal par la réduction de l'oxalate présent dans l'estomac, pour ainsi réduire l'absorption dudit oxalate, ledit procédé comprenant l'administration par voie orale de la composition dans l'estomac du sujet humain ou animal.

10 10. Composition pour son utilisation selon la revendication 9, dans laquelle la réduction de l'absorption de l'oxalate fournit un traitement pour une affection associée à l'oxalate sélectionnée dans le groupe constitué de l'hyperoxalurie, de l'hyperoxalurie absorptive, de l'hyperoxalurie entérique, de l'hyperoxalurie primaire, des calculs rénaux idiopathiques à base d'oxalate de calcium, de la lithiase urinaire, de la vulvodynie, d'une oxalose associée à une maladie rénale en stade terminal, des troubles de la conduction cardiaque, d'une affection abdominale inflammatoire, de la maladie de Crohn, de la rectocolite hémorragique, des affections post-chirurgie gastro-intestinale, et des affections post-chirurgie digestive de l'obésité, des affections post-chirurgie pour l'obésité, ou d'un traitement post-antibiotique.

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

### Patent documents cited in the description

- WO 2007075447 A [0010] [0011]

### Non-patent literature cited in the description

- **SVEDRUZIC D. et al.** The enzymes of oxalate metabolism: Unexpected structures and metabolism. *Arch Biochem Biophys.*, 01 January 2005, vol. 433 (1), 176-92 [0016]

Rekombináns oxalát-degradáló enzimek tisztítása és izolálása és porlasztva szárított oxalát-degradáló enzimeket tartalmazó részecskék

### Szabadalmi igénypontok

1. Porlasztva szárított részecskék, melyek egy vagy több, az 1. vagy 2. számú szekvenciával rendelkező oxalát dekarboxiláz (OxDC) vad típusú rekombináns protein C383S és C383A mutáns, vagy egy 3., 4., 5., 6., 7., 8., 15., 16., 17., 18. vagy 19. számú szekvencia által kódolt protein közül választott rekombináns proteint; és egy polimer anyagot tartalmaznak, ahol a proteinek nano- vagy mikroagglomerátumként vannak előállítva.
2. Az 1. igénypont szerinti porlasztva szárított részecskék, ahol az oxalát redukáló enzim az (OxDC) vad típusú rekombináns protein C383S mutánsa vagy egy 3., 4., 5., 6., 7. vagy 8. számú szekvencia által kódolt protein.
3. Az 1. igénypont szerinti porlasztva szárított részecskék, ahol az oxalát redukáló enzim az (OxDC) vad típusú rekombináns protein C383A mutánsa vagy egy 15., 16., 17., 18. vagy 19. számú szekvencia által kódolt protein.
4. Az 1-3. igénypontok bármelyike szerinti porlasztva szárított részecskék, ahol az egy vagy több oxalát redukáló enzim aktivitása, amennyiben jelen vannak a részecskékben, legfeljebb körülbelül 30 %-ig csökken, körülbelül 3,2 pH-értékű 3,2 mg/ml pepszin-oldatban 40 percen át történő inkubálás során, az eredeti aktivitást 100 %-nak tekintve.
5. Az 1-4. igénypontok bármelyike szerinti porlasztva szárított részecskék, ahol a polimer anyag poli(met)akrilát.
6. Az 1-5. igénypontok bármelyike szerinti porlasztva szárított részecskéket tartalmazó készítmény.
7. A 6. igénypont szerinti készítmény, ahol a készítmény orális dózisforma.

8. A 6. vagy 7. igénypont szerinti készítmény, mely tasak, tabletta, kapszula, rágótabletta, gyorsan oldódó tabletta, szájban széteső tabletta, folyadék, szirup vagy elixír formájú.

9. A 6-8. igénypontok bármelyike szerinti készítmény ember vagy állat kezelési eljárásában történő alkalmazásra, melynek során az alany gyomrában jelenlévő oxalátot redukáljuk, így módon az oxalát abszorpcióját csökkentve, mely eljárás során az emberi vagy állati alany gyomrába adagoljuk a készítményt.

10. A készítmény a 9. igénypont szerinti alkalmazásra, ahol az oxalát abszorpciójának csökkentése hyperoxaluria, abszorptív hyperoxaluria, enterális hyperoxaluria, primer hyperoxaluria, idiopathiás kalciumoxalát vesekő betegség, urolithiasis, vulvodinia, végső stádiumú vesebetegséggel összefüggő oxalosis, szív konduktancia rendellenesség, gyulladásos bélbetegség, Crohn-betegség, fekélyes colitis, gyomor- és bélrendszeri operációt követő állapotok, és elhízást kezelő operációt követő állapotok, kövérségi operációt követő állapotok vagy antibiotikumos kezelés követő állapotok közül választott oxaláttal összefüggő állapot kezelését biztosítja.

Szentpéteri Zsolt  
Szakmai ügyintéző  
SSEK Szakmai Ügyintéző Iroda  
H-1062 Budapest, Andrássy út 113.  
Telefon: 46 411 100  
Email: szentpeteri\_zs@szek.hu